Everting heart valve

Description

BACKGROUND OF THE INVENTION

The present invention relates to methods and apparatus for endovascularly replacing a heart valve. More particularly, the present invention relates to methods and apparatus for endovascularly replacing a heart valve with a replacement valve and an expandable and retrievable anchor. The replacement valve preferably is not connected to the expandable anchor and may be wrapped about an end of the anchor, for example, by everting during endovascular deployment.

Heart valve surgery is used to repair or replace diseased heart valves. Valve surgery is an open-heart procedure conducted under general anesthesia. An incision is made through the patient's sternum (sternotomy), and the patient's heart is stopped while blood flow is rerouted through a heart-lung bypass machine.

Valve replacement may be indicated when there is a narrowing of the native heart valve, commonly referred to as stenosis, or when the native valve leaks or regurgitates. When replacing the valve, the native valve is excised and replaced with either a biologic or a mechanical valve. Mechanical valves require lifelong anticoagulant medication to prevent blood clot formation, and clicking of the valve often may be heard through the chest. Biologic tissue valves typically do not require such medication. Tissue valves may be obtained from cadavers or may be porcine or bovine, and are commonly attached to synthetic rings that are secured to the patient's heart.

Valve replacement surgery is a highly invasive operation with significant concomitant risk. Risks include bleeding, infection, stroke, heart attack, arrhythmia, renal failure, adverse reactions to the anesthesia medications, as well as sudden death. 2-5% of patients die during surgery.

Post-surgery, patients temporarily may be confused due to emboli and other factors associated with the heart-lung machine. The first 2-3 days following surgery are spent in an intensive care unit where heart functions can be closely monitored. The average hospital stay is between 1 to 2 weeks, with several more weeks to months required for complete recovery.

In recent years, advancements in minimally invasive surgery and interventional cardiology have encouraged some investigators to pursue percutaneous replacement of the aortic heart valve. See, e.g., U.S. Pat. No. 6,168,614. In many of these procedures, the replacement valve is deployed across the native diseased valve to permanently hold the valve open, thereby alleviating a need to excise the native valve and to position the replacement valve in place of the native valve.

In the endovascular aortic valve replacement procedure, accurate placement of aortic valves relative to coronary ostia and the mitral valve is critical. Standard self-expanding systems have very poor accuracy in deployment, however. Often the proximal end of the stent is not released from the delivery system until accurate placement is verified by fluoroscopy, and the stent typically jumps once released. It is therefore often impossible to know where the ends of the stent will be with respect to the native valve, the coronary ostia and the mitral valve.

Also, visualization of the way the new valve is functioning prior to final deployment is very desirable. Visualization prior to final and irreversible deployment cannot be done with standard self-expanding systems, however, and the replacement valve is often not fully functional before final deployment.

Another drawback of prior art self-expanding replacement heart valve systems is their lack of radial strength. In order for self-expanding systems to be easily delivered through a delivery sheath, the metal needs to flex and bend inside the delivery catheter without being plastically deformed. In arterial stents, this is not a challenge, and there are many commercial arterial stent systems that apply adequate radial force against the vessel wall and yet can collapse to a small enough of a diameter to fit inside a delivery catheter without plastic deformation. However when the stent has a valve fastened inside it, as is the case in aortic valve replacement, the anchoring of the stent to vessel walls is significantly challenged during diastole. The force to hold back arterial pressure and prevent blood from going back inside the ventricle during diastole will be directly transferred to the stent/vessel wall interface. Therefore, the amount of radial force required to keep the self-expanding stent/valve in contact with the vessel wall and not sliding will be much higher than in stents that do not have valves inside of them. Moreover, a self-expanding stent without sufficient radial force will end up dilating and contracting with each heartbeat, thereby distorting the valve, affecting its function and possibly migrating and dislodging completely. Simply increasing strut thickness of the self-expanding stent is not a practical solution as it runs the risk of larger profile and/or plastic deformation of the self-expanding stent.

In view of drawbacks associated with previously known techniques for endovascularly replacing a heart valve, it would be desirable to provide methods and apparatus that overcome those drawbacks.

SUMMARY OF THE INVENTION

One aspect of the present invention provides apparatus for endovascularly replacing a patient's heart valve, the apparatus including: a replacement valve; and an expandable anchor, wherein the replacement valve and expandable anchor are configured for endovascular delivery to the vicinity of the heart valve, and wherein at least a portion of the replacement valve is configured to evert about the anchor during endovascular deployment.

Another aspect of the invention provides a method for endovascularly replacing a patient's heart valve. In some embodiments the method includes the steps of: endovascularly delivering a replacement valve and an expandable anchor to a vicinity of the heart valve; everting at least a portion of the replacement valve about the anchor; and expanding the anchor to a deployed configuration.

Yet another aspect of the invention provides apparatus for endovascularly replacing a patient's heart valve including: an anchor comprising a lip region and a skirt region; and a replacement valve, wherein at least a portion of the replacement valve is configured to evert about the anchor during endovascular deployment, and wherein the lip region and skirt region are configured for percutaneous expansion to engage the patient's heart valve.

Still another aspect of the present invention provides a method for endovascularly replacing a patient's heart valve, the method including: endovascularly delivering a replacement valve and an expandable anchor to a vicinity of the heart valve, endovascularly wrapping at least a portion of the replacement valve about the anchor, and expanding the anchor to a deployed configuration.

Another aspect of the present invention provides apparatus for endovascularly replacing a patient's heart valve, the apparatus including: a replacement valve, and an expandable anchor, wherein the replacement valve and the anchor are configured for endovascular delivery to a vicinity of the patient's heart valve, and wherein at least a portion of the replacement valve is wrapped about an end of the anchor in a deployed configuration.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

FIGS. 1A-B are elevational views of a replacement heart valve and anchor according to one embodiment of the invention.

FIGS. 2A-B are sectional views of the anchor and valve of FIG. 1.

FIGS. 3A-B show delivery and deployment of a replacement heart valve and anchor, such as the anchor and valve of FIGS. 1 and 2.

FIGS. 4A-F also show delivery and deployment of a replacement heart valve and anchor, such as the anchor and valve of FIGS. 1 and 2.

FIGS. 5A-F show the use of a replacement heart valve and anchor to replace an aortic valve.

FIGS. 6A-F show the use of a replacement heart valve and anchor with a positive registration feature to replace an aortic valve.

FIG. 7 shows the use of a replacement heart valve and anchor with an alternative positive registration feature to replace an aortic valve.

FIGS. 8A-C show another embodiment of a replacement heart valve and anchor according to the invention.

FIGS. 9A-H show delivery and deployment of the replacement heart valve and anchor of FIG. 8.

FIG. 10 is a cross-sectional drawing of the delivery system used with the method and apparatus of FIGS. 8 and 9.

FIGS. 11A-C show alternative locks for use with replacement heart valves and anchors of this invention.

FIGS. 12A-C show a vessel wall engaging lock for use with replacement heart valves and anchors of this invention.

FIG. 13 demonstrates paravalvular leaking around a replacement heart valve and anchor.

FIG. 14 shows a seal for use with a replacement heart valve and anchor of this invention.

FIGS. 15A-E show alternative arrangements of seals on a replacement heart valve and anchor.

FIGS. 16A-C show alternative seal designs for use with replacement heart valves and anchors.

FIGS. 17A-B show an alternative anchor lock embodiment in an unlocked configuration.

FIGS. 18A-B show the anchor lock of FIG. 17 in a locked configuration.

FIG. 19 shows an alternative anchor deployment tool attachment and release mechanism for use with the invention.

FIG. 20 shows the attachment and release mechanism of FIG. 19 in the process of being released.

FIG. 21 shows the attachment and release mechanism of FIGS. 19 and 20 in a released condition.

FIG. 22 shows an alternative embodiment of a replacement heart valve and anchor and a deployment tool according to the invention in an undeployed configuration.

FIG. 23 shows the replacement heart valve and anchor of FIG. 22 in a partially deployed configuration.

FIG. 24 shows the replacement heart valve and anchor of FIGS. 22 and 23 in a more fully deployed configuration but with the deployment tool still attached.

FIG. 25 shows yet another embodiment of the delivery and deployment apparatus of the invention in use with a replacement heart valve and anchor.

FIG. 26 shows the delivery and deployment apparatus of FIG. 25 in the process of deploying a replacement heart valve and anchor.

FIG. 27 shows an embodiment of the invention employing seals at the interface of the replacement heart valve and anchor and the patient's tissue.

FIG. 28 is a longitudinal cross-sectional view of the seal shown in FIG. 27 in compressed form.

FIG. 29 is a transverse cross-sectional view of the seal shown in FIG. 28.

FIG. 30 is a longitudinal cross-sectional view of the seal shown in FIG. 27 in expanded form.

FIG. 31 is a transverse cross-sectional view of the seal shown in FIG. 30.

FIG. 32 shows yet another embodiment of the replacement heart valve and anchor of this invention in an undeployed configuration.

FIG. 33 shows the replacement heart valve and anchor of FIG. 32 in a deployed configuration.

FIG. 34 shows the replacement heart valve and anchor of FIGS. 32 and 33 deployed in a patient's heart valve.

FIGS. 35A-H show yet another embodiment of a replacement heart valve, anchor and deployment system according to this invention.

FIGS. 36A-E show more detail of the anchor of the embodiment shown in FIGS. 35A-H.

FIGS. 37A-B show other embodiments of the replacement heart valve and anchor of the invention.

FIGS. 38A-C illustrate a method for endovascularly replacing a patient's diseased heart valve.

FIGS. 39A-G are side views, partially in section, as well as an isometric view, illustrating a method for endovascularly replacing a patient's diseased heart valve with an embodiment of the present invention comprising a replacement valve that is not connected to the expandable anchor, the replacement valve wrapped about the anchor, illustratively by everting during deployment.

FIGS. 40A-D are side views, partially in section, illustrating a method for endovascularly replacing a patient's diseased heart valve with another everting embodiment of the present invention.

FIGS. 41A-E are side views, partially in section, illustrating a method for endovascularly replacing a patient's diseased heart valve with yet another everting embodiment of the present invention, wherein the replacement valve and the anchor are telescoped relative to one another during endovascular delivery.

FIGS. 42A-B are side-sectional views of alternative everting apparatus comprising everting valve leaflets.

FIGS. 43A-B, are side-sectional views of further alternative everting apparatus comprising a locking mechanism coupled to the everting segment.

FIGS. 44A-B are side-sectional views of telescoping embodiments of the present invention comprising U-shaped valve frames.

DETAILED DESCRIPTION OF THE INVENTION

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. For example, for the two-part locking mechanisms described hereinafter, it will be apparent that the locations of the male and female elements may be reversed. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

With reference now to FIGS. 1-4, a first embodiment of replacement heart valve apparatus in accordance with the present invention is described, including a method of actively foreshortening and expanding the apparatus from a delivery configuration and to a deployed configuration. Apparatus 10 comprises replacement valve 20 disposed within and coupled to anchor 30. FIG. 1 schematically illustrate individual cells of anchor 30 of apparatus 10, and should be viewed as if the cylindrical anchor has been cut open and laid flat. FIG. 2 schematically illustrate a detail portion of apparatus 10 in side-section.

Anchor 30 has a lip region 32, a skirt region 34 and a body region 36. First, second and third posts 38a, 38b and 38c, respectively, are coupled to skirt region 34 and extend within lumen 31 of anchor 30. Posts 38 preferably are spaced 120.degree. apart from one another about the circumference of anchor 30.

Anchor 30 preferably is fabricated by using self-expanding patterns (laser cut or chemically milled), braids and materials, such as a stainless steel, nickel-titanium (“Nitinol”) or cobalt chromium, but alternatively may be fabricated using balloon-expandable patterns where the anchor is designed to plastically deform to its final shape by means of balloon expansion. Replacement valve 20 is preferably made from biologic tissues, e.g. porcine valve leaflets or bovine or equine pericardium tissues or human cadaver tissue. Alternatively, it can be made from tissue engineered materials (such as extracellular matrix material from Small Intestinal Submucosa (SIS)) or may be prosthetic and made from an elastomeric polymer or silicone, Nitinol or stainless steel mesh or pattern (sputtered, chemically milled or laser cut). The leaflet may also be made of a composite of the elastomeric or silicone materials and metal alloys or other fibers such Kevlar or carbon Annular base 22 of replacement valve 20 preferably is coupled to skirt region 34 of anchor 30, while commissures 24 of replacement valve leaflets 26 are coupled to and supported by posts 38.

Anchor 30 may be actuated using external non-hydraulic or non-pneumatic force to actively foreshorten in order to increase its radial strength. As shown below, the proximal and distal end regions of anchor 30 may be actuated independently. The anchor and valve may be placed and expanded in order to visualize their location with respect to the native valve and other anatomical features and to visualize operation of the valve. The anchor and valve may thereafter be repositioned and even retrieved into the delivery sheath or catheter. The apparatus may be delivered to the vicinity of the patient's aortic valve in a retrograde approach in a catheter having a diameter no more than 23 french, preferably no more than 21 french, more preferably no more than 19 french, or more preferably no more than 17 french. Upon deployment the anchor and replacement valve capture the native valve leaflets and positively lock to maintain configuration and position.

A deployment tool is used to actuate, reposition, lock and/or retrieve anchor 30. In order to avoid delivery of anchor 30 on a balloon for balloon expansion, a non-hydraulic or non-pneumatic anchor actuator is used. In this embodiment, the actuator is a deployment tool that includes distal region control wires 50, control rods or tubes 60 and proximal region control wires 62. Locks 40 include posts or arms 38 preferably with male interlocking elements 44 extending from skirt region 34 and mating female interlocking elements 42 in lip region 32. Male interlocking elements 44 have eyelets 45. Control wires 50 pass from a delivery system for apparatus 10 through female interlocking elements 42, through eyelets 45 of male interlocking elements 44, and back through female interlocking elements 42, such that a double strand of wire 50 passes through each female interlocking element 42 for manipulation by a medical practitioner external to the patient to actuate and control the anchor by changing the anchor's shape. Control wires 50 may comprise, for example, strands of suture.

Tubes 60 are reversibly coupled to apparatus 10 and may be used in conjunction with wires 50 to actuate anchor 30, e.g., to foreshorten and lock apparatus 10 in the fully deployed configuration. Tubes 60 also facilitate repositioning and retrieval of apparatus 10, as described hereinafter. For example, anchor 30 may be foreshortened and radially expanded by applying a distally directed force on tubes 60 while proximally retracting wires 50. As seen in FIG. 3, control wires 62 pass through interior lumens 61 of tubes 60. This ensures that tubes 60 are aligned properly with apparatus 10 during deployment and foreshortening. Control wires 62 can also actuate anchor 60; proximally directed forces on control wires 62 contacts the proximal lip region 32 of anchor 30. Wires 62 also act to couple and decouple tubes 60 from apparatus 10. Wires 62 may comprise, for example, strands of suture.

FIGS. 1A and 2A illustrate anchor 30 in a delivery configuration or in a partially deployed configuration (e.g., after dynamic self-expansion from a constrained delivery configuration within a delivery sheath). Anchor 30 has a relatively long length and a relatively small width in the delivery or partially deployed configuration, as compared to the foreshortened and fully deployed configuration of FIGS. 1B and 2B.

In FIGS. 1A and 2A, replacement valve 20 is collapsed within lumen 31 of anchor 30. Retraction of wires 50 relative to tubes 60 foreshortens anchor 30, which increases the anchor's width while decreasing its length. Such foreshortening also properly seats replacement valve 20 within lumen 31 of anchor 30. Imposed foreshortening will enhance radial force applied by apparatus 10 to surrounding tissue over at least a portion of anchor 30. In some embodiments, the anchor is capable of exerting an outward radial force on surrounding tissue to engage the tissue in such way to prevent migration of anchor. This outward radial force is preferably greater than 2 psi, more preferably greater than 4 psi, more preferably greater than 6 psi, more preferably greater than 8 psi, more preferably greater than 10 psi, more preferably greater than 20 psi, or more preferably greater than 30 psi. Enhanced radial force of the anchor is also important for enhanced crush resistance of the anchor against the surrounding tissue due to the healing response (fibrosis and contraction of annulus over a longer period of time) or to dynamic changes of pressure and flow at each heart beat. In an alternative embodiment, the anchor pattern or braid is designed to have gaps or areas where the native tissue is allowed to protrude through the anchor slightly (not shown) and, as the foreshortening is applied, the tissue and anchor become intertwined and immobilized. This feature would provide additional means to prevent anchor migration and enhance long-term stability of the device.

Deployment of apparatus 10 is fully reversible until lock 40 has been locked via mating of male interlocking elements 44 with female interlocking elements 42. Deployment is then completed by decoupling tubes 60 from lip section 32 of anchor 30 by retracting one end of each wire 62 relative to the other end of the wire, and by retracting one end of each wire 50 relative to the other end of the wire until each wire has been removed from eyelet 45 of its corresponding male interlocking element 44.

As best seen in FIG. 2B, body region 36 of anchor 30 optionally may comprise barb elements 37 that protrude from anchor 30 in the fully deployed configuration, for example, for engagement of a patient's native valve leaflets and to preclude migration of the apparatus.

With reference now to FIG. 3, a delivery and deployment system for a self-expanding embodiment of apparatus 10 including a sheath 110 having a lumen 112. Self-expanding anchor 30 is collapsible to a delivery configuration within lumen 112 of sheath 110, such that apparatus 10 may be delivered via delivery system 100. As seen in FIG. 3A, apparatus 10 may be deployed from lumen 112 by retracting sheath 110 relative to apparatus 10, control wires 50 and tubes 60, which causes anchor 30 to dynamically self-expand to a partially deployed configuration. Control wires 50 then are retracted relative to apparatus 10 and tubes 60 to impose foreshortening upon anchor 30, as seen in FIG. 3B.

During foreshortening, tubes 60 push against lip region 32 of anchor 30, while wires 50 pull on posts 38 of the anchor. Wires 62 may be retracted along with wires 50 to enhance the distally directed pushing force applied by tubes 60 to lip region 32. Continued retraction of wires 50 relative to tubes 60 would lock locks 40 and fully deploy apparatus 10 with replacement valve 20 properly seated within anchor 30, as in FIGS. 1B and 2B. Apparatus 10 comprises enhanced radial strength in the fully deployed configuration as compared to the partially deployed configuration of FIG. 3A. Once apparatus 10 has been fully deployed, wires 50 and 62 may be removed from apparatus 10, thereby separating delivery system 100 and tubes 60 from the apparatus.

Deployment of apparatus 10 is fully reversible until locks 40 have been actuated. For example, just prior to locking the position of the anchor and valve and the operation of the valve may be observed under fluoroscopy. If the position needs to be changed, by alternately relaxing and reapplying the proximally directed forces exerted by control wires 50 and/or control wires 62 and the distally directed forces exerted by tubes 60, expansion and contraction of the lip and skirt regions of anchor 30 may be independently controlled so that the anchor and valve can be moved to, e.g., avoid blocking the coronary ostia or impinging on the mitral valve. Apparatus 10 may also be completely retrieved within lumen 112 of sheath 110 by simultaneously proximally retracting wires 50 and tubes 60/wires 62 relative to sheath 110. Apparatus 10 then may be removed from the patient or repositioned for subsequent redeployment.

Referring now to FIG. 4, step-by-step deployment of apparatus 10 via delivery system 100 is described. In FIG. 4A, sheath 110 is retracted relative to apparatus 10, wires 50 and tubes 60, thereby causing self-expandable anchor 30 to dynamically self-expand apparatus 10 from the collapsed delivery configuration within lumen 112 of sheath 110 to the partially deployed configuration. Apparatus 10 may then be dynamically repositioned via tubes 60 to properly orient the apparatus, e.g. relative to a patient's native valve leaflets.

In FIG. 4B, control wires 50 are retracted while tubes 60 are advanced, thereby urging lip region 32 of anchor 30 in a distal direction while urging posts 38 of the anchor in a proximal direction. This foreshortens apparatus 10, as seen in FIG. 4C. Deployment of apparatus 10 is fully reversible even after foreshortening has been initiated and has advanced to the point illustrated in FIG. 4C.

In FIG. 4D, continued foreshortening causes male interlocking elements 44 of locks 40 to engage female interlocking elements 42. The male elements mate with the female elements, thereby locking apparatus 10 in the foreshortened configuration, as seen in FIG. 4E. Wires 50 are then pulled through eyelets 45 of male elements 44 to remove the wires from apparatus 10, and wires 62 are pulled through the proximal end of anchor 30 to uncouple tubes 60 from the apparatus, thereby separating delivery system 100 from apparatus 10. Fully deployed apparatus 10 is shown in FIG. 4F.

Referring to FIG. 5, a method of endovascularly replacing a patient's diseased aortic valve with apparatus 10 and delivery system 100 is described. As seen in FIG. 5A, sheath 110 of delivery system 100, having apparatus 10 disposed therein, is endovascularly advanced over guide wire G, preferably in a retrograde fashion (although an antegrade or hybrid approach alternatively may be used), through a patient's aorta A to the patient's diseased aortic valve AV. A nosecone 102 precedes sheath 110 in a known manner. In FIG. 5B, sheath 110 is positioned such that its distal region is disposed within left ventricle LV of the patient's heart H.

Apparatus 10 is deployed from lumen 112 of sheath 110, for example, under fluoroscopic guidance, such that anchor 30 of apparatus 10 dynamically self-expands to a partially deployed configuration, as in FIG. 5C. Advantageously, apparatus 10 may be retracted within lumen 112 of sheath 110 via wires 50—even after anchor 30 has dynamically expanded to the partially deployed configuration, for example, to abort the procedure or to reposition apparatus 10 or delivery system 100. As yet another advantage, apparatus 10 may be dynamically repositioned, e.g. via sheath 110 and/or tubes 60, in order to properly align the apparatus relative to anatomical landmarks, such as the patient's coronary ostia or the patient's native valve leaflets L. When properly aligned, skirt region 34 of anchor 30 preferably is disposed distal of the leaflets, while body region 36 is disposed across the leaflets and lip region 32 is disposed proximal of the leaflets.

Once properly aligned, wires 50 are retracted relative to tubes 60 to impose foreshortening upon anchor 30 and expand apparatus 10 to the fully deployed configuration, as in FIG. 5D. Foreshortening increases the radial strength of anchor 30 to ensure prolonged patency of valve annulus An, as well as to provide a better seal for apparatus 10 that reduces paravalvular regurgitation. As seen in FIG. 5E, locks 40 maintain imposed foreshortening. Replacement valve 20 is properly seated within anchor 30, and normal blood flow between left ventricle LV and aorta A is thereafter regulated by apparatus 10. Deployment of apparatus 10 advantageously is fully reversible until locks 40 have been actuated.

As seen in FIG. 5F, wires 50 are pulled from eyelets 45 of male elements 44 of locks 40, tubes 60 are decoupled from anchor 30, e.g. via wires 62, and delivery system 100 is removed from the patient, thereby completing deployment of apparatus 10. Optional barb elements 37 engage the patient's native valve leaflets, e.g. to preclude migration of the apparatus and/or reduce paravalvular regurgitation.

With reference now to FIG. 6, a method of endovascularly replacing a patient's diseased aortic valve with apparatus 10 is provided, wherein proper positioning of the apparatus is ensured via positive registration of a modified delivery system to the patient's native valve leaflets. In FIG. 6A, modified delivery system 100′ delivers apparatus 10 to diseased aortic valve AV within sheath 110. As seen in FIGS. 6B and 6C, apparatus 10 is deployed from lumen 112 of sheath 110, for example, under fluoroscopic guidance, such that anchor 30 of apparatus 10 dynamically self-expands to a partially deployed configuration. As when deployed via delivery system 100, deployment of apparatus 10 via delivery system 100′ is fully reversible until locks 40 have been actuated.

Delivery system 100′ comprises leaflet engagement element 120, which preferably self-expands along with anchor 30. Engagement element 120 is disposed between tubes 60 of delivery system 100′ and lip region 32 of anchor 30. Element 120 releasably engages the anchor. As seen in FIG. 6C, the element is initially deployed proximal of the patient's native valve leaflets L. Apparatus 10 and element 120 then may be advanced/dynamically repositioned until the engagement element positively registers against the leaflets, thereby ensuring proper positioning of apparatus 10. Also, delivery system 100′ includes filter structure 61A (e.g., filter membrane or braid) as part of push tubes 60 to act as an embolic protection element. Emboli can be generated during manipulation and placement of anchor, from either diseased native leaflet or surrounding aortic tissue, and can cause blockage. Arrows 61B in FIG. 6E show blood flow through filter structure 61A where blood is allowed to flow but emboli is trapped in the delivery system and removed with it at the end of the procedure.

Alternatively, foreshortening may be imposed upon anchor 30 while element 120 is disposed proximal of the leaflets, as in FIG. 6D. Upon positive registration of element 120 against leaflets L, element 120 precludes further distal migration of apparatus 10 during additional foreshortening, thereby reducing a risk of improperly positioning the apparatus. FIG. 6E details engagement of element 120 against the native leaflets. As seen in FIG. 6F, once apparatus 10 is fully deployed, element 120, wires 50 and tubes 60 are decoupled from the apparatus, and delivery system 100′ is removed from the patient, thereby completing the procedure.

With reference to FIG. 7, an alternative embodiment of the apparatus of FIG. 6 is described, wherein leaflet engagement element 120 is coupled to anchor 30 of apparatus 10′, rather than to delivery system 100. Engagement element 120 remains implanted in the patient post-deployment of apparatus 10′. Leaflets L are sandwiched between lip region 32 of anchor 30 and element 120 in the fully deployed configuration. In this manner, element 120 positively registers apparatus 10′ relative to the leaflets and precludes distal migration of the apparatus over time.

Referring now to FIG. 8, an alternative delivery system adapted for use with a balloon expandable embodiment of the present invention is described. In FIG. 8A, apparatus 10″ comprises anchor 30′ that may be fabricated from balloon-expandable materials. Delivery system 100″ comprises inflatable member 130 disposed in a deflated configuration within lumen 31 of anchor 30′. In FIG. 8B, optional outer sheath 110 is retracted, and inflatable member 130 is inflated to expand anchor 30′ to the fully deployed configuration. As inflatable member 130 is being deflated, as in earlier embodiments, wires 50 and 62 and tubes 60 may be used to assist deployment of anchor 30′ and actuation of locks 40, as well as to provide reversibility and retrievability of apparatus 10″ prior to actuation of locks 40. Next, wires 50 and 62 and tubes 60 are removed from apparatus 10″, and delivery system 100″ is removed, as seen in FIG. 8C.

As an alternative delivery method, anchor 30′ may be partially deployed via partial expansion of inflatable member 130. The inflatable member would then be advanced within replacement valve 20 prior to inflation of inflatable member 130 and full deployment of apparatus 10″. Inflation pressures used will range from about 3 to 6 atm, or more preferably from about 4 to 5 atm, though higher and lower atm pressures may also be used (e.g., greater than 3 atm, more preferably greater than 4 atm, more preferably greater than 5 atm, or more preferably greater than 6 atm). Advantageously, separation of inflatable member 130 from replacement valve 20, until partial deployment of apparatus 10″ at a treatment site, is expected to reduce a delivery profile of the apparatus, as compared to previously known apparatus. This profile reduction may facilitate retrograde delivery and deployment of apparatus 10″, even when anchor 30′ is balloon-expandable.

Although anchor 30′ has illustratively been described as fabricated from balloon-expandable materials, it should be understood that anchor 30′ alternatively may be fabricated from self-expanding materials whose expansion optionally may be balloon-assisted. In such a configuration, anchor 30′ would expand to a partially deployed configuration upon removal of outer sheath 110. If required, inflatable member 130 then would be advanced within replacement valve 20 prior to inflation. Inflatable member 130 would assist full deployment of apparatus 10″, for example, when the radial force required to overcome resistance from impinging tissue were too great to be overcome simply by manipulation of wires 50 and tubes 60. Advantageously, optional placement of inflatable member 130 within replacement valve 20, only after dynamic self-expansion of apparatus 10″ to the partially deployed configuration at a treatment site, is expected to reduce a delivery profile of the apparatus, as compared to previously known apparatus. This reduction may facilitate retrograde delivery and deployment of apparatus 10″.

With reference to FIGS. 9 and 10, methods and apparatus for a balloon-assisted embodiment of the present invention are described in greater detail. FIGS. 9 and 10 illustratively show apparatus 10′ of FIG. 7 used in combination with delivery system 100″ of FIG. 8. FIG. 10 illustrates a sectional view of delivery system 100″ Inner shaft 132 of inflatable member 130 preferably is about 4 Fr in diameter, and comprises lumen 133 configured for passage of guidewire G, having a diameter of about 0.035″, therethrough. Push tubes 60 and pull wires 50 pass through guidetube 140, which preferably has a diameter of about 15 Fr or smaller. Guide tube 140 is disposed within lumen 112 of outer sheath 110, which preferably has a diameter of about 17 Fr or smaller.

In FIG. 9A, apparatus 10′ is delivered to diseased aortic valve AV within lumen 112 of sheath 110. In FIG. 9B, sheath 110 is retracted relative to apparatus 10′ to dynamically self-expand the apparatus to the partially deployed configuration. Also retracted and removed is nosecone 102, which is attached to a pre-slit lumen (not shown) that facilitates its removal prior to loading and advancing of a regular angioplasty balloon catheter over guidewire and inside delivery system 110.

In FIG. 9C, pull wires 50 and push tubes 60 are manipulated from external to the patient to foreshorten anchor 30 and sufficiently expand lumen 31 of the anchor to facilitate advancement of inflatable member 130 within replacement valve 20. Also shown is the tip of an angioplasty catheter 130 being advanced through delivery system 110.

The angioplasty balloon catheter or inflatable member 130 then is advanced within the replacement valve, as in FIG. 9D, and additional foreshortening is imposed upon anchor 30 to actuate locks 40, as in FIG. 9E. The inflatable member is inflated to further displace the patient's native valve leaflets L and ensure adequate blood flow through, and long-term patency of, replacement valve 20, as in FIG. 9F. Inflatable member 130 then is deflated and removed from the patient, as in FIG. 9G. A different size angioplasty balloon catheter could be used repeat the same step if deemed necessary by the user. Push tubes 60 optionally may be used to further set leaflet engagement element 120, or optional barbs B along posts 38, more deeply within leaflets L, as in FIG. 9H. Then, delivery system 100″ is removed from the patient, thereby completing percutaneous heart valve replacement.

As will be apparent to those of skill in the art, the order of imposed foreshortening and balloon expansion described in FIGS. 9 and 10 is only provided for the sake of illustration. The actual order may vary according to the needs of a given patient and/or the preferences of a given medical practitioner. Furthermore, balloon-assist may not be required in all instances, and the inflatable member may act merely as a safety precaution employed selectively in challenging clinical cases.

Referring now to FIG. 11, alternative locks for use with apparatus of the present invention are described. In FIG. 11A, lock 40′ comprises male interlocking element 44 as described previously. However, female interlocking element 42′ illustratively comprises a triangular shape, as compared to the round shape of interlocking element 42 described previously. The triangular shape of female interlocking element 42′ may facilitate mating of male interlocking element 44 with the female interlocking element without necessitating deformation of the male interlocking element.

In FIG. 11B, lock 40″ comprises alternative male interlocking element 44′ having multiple in-line arrowheads 46 along posts 38. Each arrowhead comprises resiliently deformable appendages 48 to facilitate passage through female interlocking element 42. Appendages 48 optionally comprise eyelets 49, such that control wire 50 or a secondary wire may pass therethrough to constrain the appendages in the deformed configuration. To actuate lock 40″, one or more arrowheads 46 of male interlocking element 44′ are drawn through female interlocking element 42, and the wire is removed from eyelets 49, thereby causing appendages 48 to resiliently expand and actuate lock 40″.

Advantageously, providing multiple arrowheads 46 along posts 38 yields a ratchet that facilitates in-vivo determination of a degree of foreshortening imposed upon apparatus of the present invention. Furthermore, optionally constraining appendages 48 of arrowheads 46 via eyelets 49 prevents actuation of lock 40″ (and thus deployment of apparatus of the present invention) even after male element 44′ has been advanced through female element 42. Only after a medical practitioner has removed the wire constraining appendages 48 is lock 40″ fully engaged and deployment no longer reversible.

Lock 40″′ of FIG. 11C is similar to lock 40″ of FIG. 11B, except that optional eyelets 49 on appendages 48 have been replaced by optional overtube 47. Overtube 47 serves a similar function to eyelets 49 by constraining appendages 48 to prevent locking until a medical practitioner has determined that apparatus of the present invention has been foreshortened and positioned adequately at a treatment site. Overtube 47 is then removed, which causes the appendages to resiliently expand, thereby fully actuating lock 40″.

With reference to FIG. 12, an alternative locking mechanism is described that is configured to engage the patient's aorta. Male interlocking elements 44″ of locks 40″″ comprise arrowheads 46′ having sharpened appendages 48′. Upon expansion from the delivery configuration of FIG. 12A to the foreshortened configuration of FIG. 12B, apparatus 10 positions sharpened appendages 48′ adjacent the patient's aorta A. Appendages 48′ engage the aortic wall and reduce a risk of device migration over time.

With reference now to FIG. 13, a risk of paravalvular leakage or regurgitation around apparatus of the present invention is described. In FIG. 13, apparatus 10 has been implanted at the site of diseased aortic valve AV, for example, using techniques described hereinabove. The surface of native valve leaflets L is irregular, and interface I between leaflets L and anchor 30 may comprise gaps where blood B may seep through. Such leakage poses a risk of blood clot formation or insufficient blood flow.

Referring to FIG. 14, optional elements for reducing regurgitation or leakage are described. Compliant sacs 200 may be disposed about the exterior of anchor 30 to provide a more efficient seal along irregular interface I. Sacs 200 may be filled with an appropriate material, for example, water, blood, foam or a hydrogel. Alternative fill materials will be apparent.

With reference to FIG. 15, illustrative arrangements for sacs 200 are provided. In FIG. 15A, sacs 200 are provided as discrete sacs at different positions along the height of anchor 30. In FIG. 15B, the sacs are provided as continuous cylinders at various heights. In FIG. 15C, a single sac is provided with a cylindrical shape that spans multiple heights. The sacs of FIG. 15D are discrete, smaller and provided in larger quantities. FIG. 15E provides a spiral sac. Alternative sac configurations will be apparent to those of skill in the art.

With reference to FIG. 16, exemplary techniques for fabricating sacs 200 are provided. In FIG. 16A, sacs 200 comprise ‘fish-scale’ slots 202 that may be back-filled, for example, with ambient blood passing through replacement valve 20. In FIG. 16B, the sacs comprise pores 204 that may be used to fill the sacs. In FIG. 16C, the sacs open to lumen 31 of anchor 30 and are filled by blood washing past the sacs as the blood moves through apparatus 10.

FIGS. 17 and 18 show yet another alternative embodiment of the anchor lock. Anchor 300 has a plurality of male interlocking elements 302 having eyelets 304 formed therein. Male interlocking elements are connected to braided structure 300 by inter-weaving elements 302 (and 308) or alternatively suturing, soldering, welding, or connecting with adhesive. Valve commissures 24 are connected to male interlocking elements 302 along their length. Replacement valve 20 annular base 22 is connected to the distal end 34 of anchor 300 (or 30) as is illustrated in FIGS. 1A and 1B. Male interlocking elements 302 also include holes 306 that mate with tabs 310 extending into holes 312 in female interlocking elements 308. To lock, control wires 314 passing through eyelets 304 and holes 312 are pulled proximally with respect to the proximal end of braided anchor 300 to draw the male interlocking elements through holes 312 so that tabs 310 engage holes 306 in male interlocking elements 302. Also shown is release wires 314B that pass through eyelet 304B in female interlocking element 308. If needed, during the procedure, the user may pull on release wires 314B, thereby reversing orientation of tabs 310, releasing the anchor and allowing for repositioning of the device or its removal from the patient. Only when finally positioned as desired by the operating physician, would release wire 314B and control wire 314 be cut and removed from the patient with the delivery system.

FIGS. 19-21 show an alternative way of releasing the connection between the anchor and its actuating tubes and control wires. Control wires 62 extend through tubes 60 from outside the patient, loop through the proximal region of anchor 30 and extend partially back into tube 60. The doubled up portion of control wire 62 creates a force fit within tube 60 that maintains the control wire's position with respect to tube 60 when all control wires 62 are pulled proximally to place a proximally directed force on anchor 30. When a single control wire 62 is pulled proximally, however, the frictional fit between that control wire and the tube in which it is disposed is overcome, enabling the end 63 of control wire 62 to pull free of the tube, as shown in FIG. 21, thereby releasing anchor 30.

FIGS. 22-24 show an alternative embodiment of the anchor. Anchor 350 is made of a metal braid, such as Nitinol or stainless steel. A replacement valve 354 is disposed within anchor 350 and supported by a replacement valve support, such as the posts described in earlier embodiments. Anchor 350 preferably is fabricated from a single strand of metal wire wound into the braid. It is expected that fabricating anchor 350 from a single strand of wire will facilitate deployment of the anchor, as well as retrieval of the anchor, by more evenly distributing forces applied to the anchor. Fabrication from a single strand is also expected to facilitate coupling of replacement valve 354 to the anchor, as well as coupling and decoupling of control wires (not shown) and tubes 352 thereto. Anchor 350 is actuated in substantially the same way as anchor 30 of FIGS. 1-4 through the application of proximally and distally directed forces from control wires and tubes 352 and may be locked in its expanded deployed configuration, as described above. The employed configuration of anchor 354 may have the shape and anchoring characteristics described with respect to other embodiments as well.

The braid forming anchor 350 (as well as that forming previously described anchor 30) optionally may be locally increased in diameter, e.g. via dipping in silicone or a hydrogel, in order to provide a better or complete seal against the patient's anatomy. An improved seal is expected to reduce paravalvular leakage, as well as migration of the anchor over time. The local increase in diameter of the braid may, for example, be provided over a full radial segment of anchor 350.

FIGS. 25 and 26 show yet another embodiment of the delivery and deployment apparatus of the invention. As an alternative to the balloon expansion method described with respect to FIG. 8, in this embodiment the nosecone (e.g., element 102 of FIG. 5) is replaced by an angioplasty balloon catheter 360. Thus, angioplasty balloon catheter 360 precedes sheath 110 on guidewire G. When anchor 30 and valve 20 are expanded through the operation of tubes 60 and the control wires (not shown) as described above, balloon catheter 360 is retracted proximally within the expanded anchor and valve and expanded further as described above with respect to FIG. 8.

As an alternative, or in addition, to further expansion of balloon catheter 360 within valve 20 and expanded anchor 30 to further expand the anchor, the balloon may be deflated prior to proximal retraction within and past the valve and anchor. In this manner, balloon catheter 360 may act as an atraumatic nosecone during delivery of valve 20 and anchor 30, but then may be deflated to provide a reduced profile, as compared to a standard nosecone, during retrieval of the balloon catheter through the deployed valve. It is expected that a smaller balloon catheter 360 may be provided when the catheter is utilized merely in place of a nosecone than when the catheter is also utilized to complete expansion of anchor 30.

FIGS. 27-31 show seals 370 that expand over time to seal the interface between the anchor and valve and the patient's tissue. Seals 370 are preferably formed from Nitinol wire surrounded by an expandable foam. As shown in cross-section in FIGS. 28 and 29, at the time of deployment, the foam 372 is compressed about the wire 374 and held in the compressed form by a time-released coating 376. After deployment, coating 376 dissolves in vivo to allow foam 372 to expand, as shown in FIGS. 30 and 31.

FIGS. 32-34 show another way to seal the replacement valve against leakage. A fabric seal 380 extends from the distal end of valve 20 and back proximally over anchor 30 during delivery. When deployed, as shown in FIGS. 33 and 34, fabric seal 380 bunches up to create fabric flaps and pockets that extend into spaces formed by the native valve leaflets 382, particularly when the pockets are filled with blood in response to backflow blood pressure. This arrangement creates a seal around the replacement valve.

FIGS. 35A-H show another embodiment of a replacement heart valve apparatus in accordance with the present invention. Apparatus 450 comprises replacement valve 460 (see FIGS. 37B and 38C) disposed within and coupled to anchor 470. Replacement valve 460 is preferably biologic, e.g. porcine, but alternatively may be synthetic. Anchor 470 preferably is fabricated from self-expanding materials, such as a stainless steel wire mesh or a nickel-titanium alloy (“Nitinol”), and comprises lip region 472, skirt region 474, and body regions 476a, 476b and 476c. Replacement valve 460 preferably is coupled to skirt region 474, but alternatively may be coupled to other regions of the anchor. As described hereinbelow, lip region 472 and skirt region 474 are configured to expand and engage/capture a patient's native valve leaflets, thereby providing positive registration, reducing paravalvular regurgitation, reducing device migration, etc.

As seen in FIG. 35A, apparatus 450 is collapsible to a delivery configuration, wherein the apparatus may be delivered via delivery system 410. Delivery system 410 comprises sheath 420 having lumen 422, as well as wires 424a and 424b seen in FIGS. 35D-35G. Wires 424a are configured to expand skirt region 474 of anchor 470, as well as replacement valve 460 coupled thereto, while wires 424b are configured to expand lip region 472.

As seen in FIG. 35B, apparatus 450 may be delivered and deployed from lumen 422 of catheter 420 while the apparatus is disposed in the collapsed delivery configuration. As seen in FIGS. 35B-35D, catheter 420 is retracted relative to apparatus 450, which causes anchor 470 to dynamically self-expand to a partially deployed configuration. Wires 424a are then retracted to expand skirt region 474, as seen in FIGS. 35E and 35F. Preferably, such expansion may be maintained via locking features described hereinafter.

In FIG. 35G, wires 424b are retracted to expand lip region 472 and fully deploy apparatus 450. As with skirt region 474, expansion of lip region 472 preferably may be maintained via locking features. After both lip region 472 and skirt region 474 have been expanded, wires 424 may be removed from apparatus 450, thereby separating delivery system 410 from the apparatus. Delivery system 410 then may be removed, as seen in FIG. 35H.

As will be apparent to those of skill in the art, lip region 472 optionally may be expanded prior to expansion of skirt region 474. As yet another alternative, lip region 472 and skirt region 474 optionally may be expanded simultaneously, in parallel, in a step-wise fashion or sequentially. Advantageously, delivery of apparatus 450 is fully reversible until lip region 472 or skirt region 474 has been locked in the expanded configuration.

With reference now to FIGS. 36A-E, individual cells of anchor 470 of apparatus 450 are described to detail deployment and expansion of the apparatus. In FIG. 36A, individual cells of lip region 472, skirt region 474 and body regions 476a, 476b and 476c are shown in the collapsed delivery configuration, as they would appear while disposed within lumen 422 of sheath 420 of delivery system 410 of FIG. 35. A portion of the cells forming body regions 476, for example, every ‘nth’ row of cells, comprises locking features.

Body region 476a comprises male interlocking element 482 of lip lock 480, while body region 476b comprises female interlocking element 484 of lip lock 480. Male element 482 comprises eyelet 483. Wire 424b passes from female interlocking element 484 through eyelet 483 and back through female interlocking element 484, such that there is a double strand of wire 424b that passes through lumen 422 of catheter 420 for manipulation by a medical practitioner external to the patient. Body region 476b further comprises male interlocking element 492 of skirt lock 490, while body region 476c comprises female interlocking element 494 of the skirt lock. Wire 424a passes from female interlocking element 494 through eyelet 493 of male interlocking element 492, and back through female interlocking element 494. Lip lock 480 is configured to maintain expansion of lip region 472, while skirt lock 490 is configured to maintain expansion of skirt region 474.

In FIG. 36B, anchor 470 is shown in the partially deployed configuration, e.g., after deployment from lumen 422 of sheath 420. Body regions 476, as well as lip region 472 and skirt region 474, self-expand to the partially deployed configuration. Full deployment is then achieved by retracting wires 424 relative to anchor 470, and expanding lip region 472 and skirt region 474 outward, as seen in FIGS. 36C and 36D. As seen in FIG. 36E, expansion continues until the male elements engage the female interlocking elements of lip lock 480 and skirt lock 490, thereby maintaining such expansion (lip lock 480 shown in FIG. 36E). Advantageously, deployment of apparatus 450 is fully reversible until lip lock 480 and/or skirt lock 490 has been actuated.

With reference to FIGS. 37A-B, isometric views, partially in section, further illustrate apparatus 450 in the fully deployed and expanded configuration. FIG. 37A illustrates the wireframe structure of anchor 470, while FIG. 37B illustrates an embodiment of anchor 470 covered in a biocompatible material B. Placement of replacement valve 460 within apparatus 450 may be seen in FIG. 37B. The patient's native valve is captured between lip region 472 and skirt region 474 of anchor 470 in the fully deployed configuration (see FIG. 38B).

Referring to FIGS. 38A-C, in conjunction with FIGS. 35 and 36, a method for endovascularly replacing a patient's diseased aortic valve with apparatus 450 is described. Delivery system 410, having apparatus 450 disposed therein, is endovascularly advanced, preferably in a retrograde fashion, through a patient's aorta A to the patient's diseased aortic valve AV. Sheath 420 is positioned such that its distal end is disposed within left ventricle LV of the patient's heart H. As described with respect to FIG. 35, apparatus 450 is deployed from lumen 422 of sheath 420, for example, under fluoroscopic guidance, such that skirt section 474 is disposed within left ventricle LV, body section 476b is disposed across the patient's native valve leaflets L, and lip section 472 is disposed within the patient's aorta A. Advantageously, apparatus 450 may be dynamically repositioned to obtain proper alignment with the anatomical landmarks. Furthermore, apparatus 450 may be retracted within lumen 422 of sheath 420 via wires 424, even after anchor 470 has dynamically expanded to the partially deployed configuration, for example, to abort the procedure or to reposition sheath 420.

Once properly positioned, wires 424a are retracted to expand skirt region 474 of anchor 470 within left ventricle LV. Skirt region 474 is locked in the expanded configuration via skirt lock 490, as previously described with respect to FIG. 36. In FIG. 38A, skirt region 474 is maneuvered such that it engages the patient's valve annulus An and/or native valve leaflets L, thereby providing positive registration of apparatus 450 relative to the anatomical landmarks.

Wires 424b are then actuated external to the patient in order to expand lip region 472, as previously described in FIG. 35. Lip region 472 is locked in the expanded configuration via lip lock 480. Advantageously, deployment of apparatus 450 is fully reversible until lip lock 480 and/or skirt lock 490 has been actuated. Wires 424 are pulled from eyelets 483 and 493, and delivery system 410 is removed from the patient. As will be apparent, the order of expansion of lip region 472 and skirt region 474 may be reversed, concurrent, etc.

As seen in FIG. 38B, lip region 472 engages the patient's native valve leaflets L, thereby providing additional positive registration and reducing a risk of lip region 472 blocking the patient's coronary ostia O. FIG. 38C illustrates the same in cross-sectional view, while also showing the position of replacement valve 460. The patient's native leaflets are engaged and/or captured between lip region 472 and skirt region 474. Advantageously, lip region 472 precludes distal migration of apparatus 450, while skirt region 474 precludes proximal migration. It is expected that lip region 472 and skirt region 474 also will reduce paravalvular regurgitation.

Referring now to FIG. 39, an embodiment of apparatus in accordance with the present invention is described, wherein the replacement valve is not connected to the expandable portion of the anchor. Rather, the replacement valve is wrapped about an end of the anchor. Such wrapping may be achieved, for example, by everting the valve during endovascular deployment.

In FIG. 39, apparatus 500 comprises expandable anchor 30′ and everting replacement valve 520, as well as delivery system 100′ for endoluminally delivering and deploying the expandable anchor and everting valve. Expandable anchor 30′ illustratively is described as substantially the same as previously described anchor 30 of FIGS. 1-4; however, it should be understood that anchor 30′ alternatively may be substantially the same as anchor 300 of FIGS. 17 and 18, anchor 350 of FIGS. 24-26, or anchor 470 of FIG. 35. As with anchor 30, anchor 30′ comprises posts 38 and locks (comprised of elements 523 and 532). Alternative locks may be provided, such as locks 40′, 40″, 40″′ or 40″″ of FIGS. 11 and 12, or the reversible lock of anchor 300 described with respect to FIGS. 17 and 18.

Everting valve 520 is similar to previously described valve 20, in that commissures 524 of replacement valve leaflets 526 are coupled to and supported by posts 38 of anchor 30′. However, annular base 522 of replacement valve 520 is not coupled to anchor 30′. Rather, annular base 522 is coupled to everting segment 528 of everting replacement valve 520. Everting segment 528 is disposed distal of anchor 30′ in the delivery configuration and is configured to wrap about the distal end of the anchor during deployment, such as by everting, thereby holding (such as by friction locking) replacement valve 520 between the anchor and the patient's tissue, thereby creating a seal between the anchor and the patient's tissue. In this manner, replacement valve 520 is entirely disconnected from the expandable/collapsible portion of anchor 30′, and a delivery profile of apparatus 500 is reduced, as compared to previously described apparatus 10.

Everting segment 528 of valve 520 may be fabricated from the same material as valve leaflets 526, e.g., a biologic tissue or a polymeric material. Alternatively, the segment may comprise a fabric, such as a permeable or impermeable fabric, a fabric that promotes or retards tissue ingrowth, a sealing foam, etc. Additional materials will be apparent.

Delivery system 100′ for use with anchor 30′ and replacement valve 520, is similar to previously described delivery system 100. The delivery system comprises sheath 110′ having lumen 112′, in which anchor 30′ may be collapsed for delivery. Control wires 50, tubes 60 and control wires 62 have been provided to deploy, foreshorten, retrieve, etc., anchor 30′, as discussed previously, and optional balloon catheter 360 has been provided as a collapsible nosecone (see FIG. 25). In delivery system 100′, the posts are connected to the distal end of the anchor and the everting valve is connected to the posts. Delivery system 100′ differs from system 100 in that it further comprises eversion control wires 550, which may, for example, be fabricated from suture.

Control wires 550 are coupled to a distal region of everting segment 528 of valve 520, and then pass proximally out of the patient external to anchor 30′ for manipulation by a medical practitioner. Control wires 550 preferably are kept taut to keep everting segment 528 in tension. Upon retraction of sheath 110′ relative to anchor 30′ and valve 520 (or advancement of the anchor and valve relative to the sheath), the tension applied to segment 528 by wires 550 causes the segment to evert and wrap about the distal end of anchor 30′. Anchor 30′ then may be expanded and deployed as described previously, thereby friction locking everting segment 528 between the anchor and the patient's anatomy.

FIG. 39 illustrate a device and method for endovascularly replacing a patient's diseased aortic valve utilizing apparatus 500. In FIG. 39A, sheath 110′ of delivery system 100′, having expandable anchor 30′ and everting valve 520 disposed therein within lumen 112′, is endovascularly advanced over guide wire G, preferably in a retrograde fashion (although an antegrade or hybrid approach alternatively may be used), through a patient's aorta A to the patient's diseased aortic valve AV. Balloon catheter nosecone 360 precedes sheath 110′. Sheath 110′ is positioned such that its distal region is disposed within left ventricle LV of the patient's heart H. In FIG. 39A, wires 550 pass from segment 528 and lumen 112′ to the exterior of sheath 110′ via through-holes 111a′, and then more proximally pass back into the interior of sheath 110′ via through-holes 111b′, which are disposed proximal of anchor 30′.

FIG. 39B is a blow-up of the intersection of tubes 60, wires 62 and anchor 30′.

FIG. 39C illustrates the beginning of the everting process wherein everting segment 528 is being pulled proximally over the exterior of anchor 30′. As seen in FIG. 39C, which provides and isometric view of the device, the inflatable element of balloon catheter 360 is deflated and further distally advanced within left ventricle LV along guide wire G relative to sheath 110′. Anchor 30′ and replacement valve 520 then are advanced relative to the sheath via tubes 60 and control wires 62, thereby deploying everting segment 528 of valve 520, as well as a distal region of anchor 30′, from the distal end of lumen 112′. Tension applied to everting segment 528 via control wires 550 connected through eyelets 529 causes the segment to wrap about the distal region of anchor 30′ by everting.

In FIG. 39C, wires 550 may pass distally from everting segment 528 out the distal end of lumen 112′ of sheath 110′, then proximally along the interior surface of the sheath all the way out of the patient. Optional through-holes 111b′ allow wires 550 to be disposed within lumen 112′ along a majority of their length. Wires 550 may also pass back into multi-lumen sheath 180.

FIG. 39D provides a cross sectional view of apparatus 500 after replacement valve 520 has everted about anchor 30′. This and other cross sectional figures portray a 120.degree. view of the apparatus herein. Sheath 10′ is then retracted relative to anchor 30′ and valve 520, which deploys a remainder of the anchor and the replacement valve from lumen 112′ of the sheath. Such deployment may be conducted, for example, under fluoroscopic guidance. Anchor 30′ dynamically self-expands to a partially deployed configuration.

Advantageously, anchor 30′ and replacement valve 520 may be retrieved and retracted within the lumen of sheath 110′ via retraction of multi-lumen catheter 180 to which tubes 60 are attached and release of wires 50. Such retrieval of apparatus 500 may be achieved even after segment 528 has been wrapped about anchor 30′, and even after anchor 30′ has dynamically expanded to the partially deployed configuration. Retrieval of apparatus 500 may be utilized, for example, to abort the procedure or to reposition the apparatus. As yet another advantage, anchor 30′ and valve 520 may be dynamically repositioned, e.g. via proximal retraction of multi-lumen catheter 180 and/or release of wires 50, in order to properly align the apparatus relative to anatomical landmarks, such as the patient's coronary ostia O or the patient's native valve leaflets L.

Once properly aligned sheath 110′, tubes 60 and wires 62 are advanced relative to wires 50 and 550 to impose foreshortening upon anchor 30′, thereby expanding the anchor to the fully deployed configuration, as in FIG. 39G. Foreshortening friction locks everting segment 528 of valve 520 between anchor 30′ and annulus An/leaflets L of the patient's diseased valve, thus properly seating the valve within the anchor while providing an improved seal between the replacement and native valves that is expected to reduce paravalvular regurgitation. Foreshortening also increases a radial strength of anchor 30′, which is expected to prolong patency of valve annulus An. Furthermore, foreshortening actuates the anchor's locks, which maintain such imposed foreshortening.

Deployment of anchor 30′ and replacement valve 520 advantageously is fully reversible until the anchor locks have been actuated. Furthermore, if the anchor's locks are reversible locks or buckles, such as those described in conjunction with anchor 300 of FIGS. 17 and 18, deployment of the anchor and valve may be fully reversible even after actuation of the locks/buckles, right up until delivery system 100′ is decoupled from the replacement apparatus.

As seen in FIG. 39G, in order to complete deployment of anchor 30′ and replacement valve 520, wires 50 of delivery system 100′ are decoupled from posts 38 of anchor 30′, tubes 60 are decoupled from anchor 30′, e.g. via wires 62, and wires 550 are decoupled from friction-locked everting segment 528 of replacement valve 520. FIG. 39E illustrates how wires 50 are associated with posts 38. In one example, wires 50 are decoupled from posts 38 by pulling on one of the wires. Decoupling of the wires and tubes may also be achieved, for example, via eyelets (see FIGS. 4E, 19-21 and 39E) or via cutting of the wires. Delivery system 100′ then is removed from the patient, as are deflated balloon catheter 360 and guide wire G, both of which are retracted proximally across the replacement valve and anchor. Normal blood flow between left ventricle LV and aorta A thereafter is regulated by replacement valve 520. FIG. 39F is a blow up illustration of replacement valves 526 which are connected to everting segment 528, wherein everting segment 528 has been everted around anchor 30′.

Referring now to FIG. 40, an alternative embodiment of everting apparatus in accordance with the present invention is described, wherein the posts are connected and the everting valve is disposed within the anchor to the proximal end of the anchor in the delivery configuration. In FIG. 40, apparatus 600 comprises everting replacement valve 620 and anchor 630, as well as previously described delivery system 100′. Replacement valve 620 and anchor 630 are substantially the same as valve 520 and anchor 30′ of FIG. 39, except that valve 620 is initially seated more proximally within anchor 630, such that everting segment 628 of valve 620 is initially disposed within the anchor. Locking mechanisms as described previously may be implemented at the distal end of the post and anchor or proximal end of everted segment and anchor.

As with replacement valve 520, everting segment 628 of valve 620 is configured to wrap about the distal end of anchor 630 by everting during deployment, thereby friction locking the replacement valve between the anchor and the patient's anatomy. Furthermore, replacement valve 620 is entirely disconnected from the expandable/collapsible portion of anchor 630. In the delivery configuration, since only a single circumferential layer of valve 620 is present along any cross section of apparatus 600, a delivery profile of the apparatus is reduced, as compared to previously described apparatus 10. With apparatus 10, two circumferential layers of valve 20 are present in the cross section where annular base 22 of the valve is coupled to the expandable anchor 30.

FIG. 40 illustrate a method of endovascularly replacing a patient's diseased aortic valve utilizing apparatus 600. In FIG. 40A, apparatus 600 is endovascularly advanced into position with valve 620 and anchor 630 disposed within lumen 112′ of sheath 110′ of delivery system 100′. As seen in FIG. 40B, the valve and anchor are advanced relative to the sheath and/or the sheath is retracted relative to the valve and anchor, which deploys everting segment 628 of the valve, as well as a distal region of the anchor. Tension applied to the everting segment via control wires 550 causes the segment to evert and wrap about the distal region of anchor 630. Control wires 550 may enter the multi-lumen catheter at the distal end of the catheter or more proximally as is illustrated in 40C. Further retraction of sheath 110′ deploys a remainder of replacement valve 620 and anchor 630 from lumen 112′ of the sheath. Such deployment may be conducted, for example, under fluoroscopic guidance. Anchor 630 dynamically self-expands to a partially deployed configuration.

Once the anchor and valve have been properly aligned in relation to anatomical landmarks, foreshortening is imposed upon anchor 630 to expand the anchor to the fully deployed configuration, as in FIG. 40C. At this point, Locks may be actuated as previously described. Foreshortening friction locks everting segment 628 of valve 620 between anchor 630 and annulus An/leaflets L of the patient's diseased valve, thus properly seating the valve within the anchor while providing an improved seal between the replacement and native valves. Foreshortening also increases a radial strength of anchor 630, which is expected to prolong patency of valve annulus An. Deployed valve 620 and anchor 630 then are decoupled from delivery system 100′, as in FIG. 40D, thereby completing deployment of apparatus 600. Thereafter, normal blood flow between left ventricle LV and aorta A is regulated by replacement valve 620.

As with apparatus 500, apparatus 600 may be dynamically repositioned during deployment, for example, in order to properly align the apparatus relative to anatomical landmarks. Furthermore, apparatus 600 advantageously may be retrieved at any point at least up until actuation of optimal locks maintaining foreshortening. When the optional locks are reversible, retrieval may be achieved until valve 620 and anchor 630 are separated from delivery system 100′.

FIG. 41 illustrate an alternative embodiment of the present invention wherein the everting valve is distal to the anchor and the posts are not connected to the braid in the delivery configuration. As is illustrated in FIG. 41A, apparatus 700 comprises everting valve 720 and expandable anchor 730, as well as delivery system 750. Delivery system 750 includes multi-lumen catheter 180. Anchor 730 is fabricated from an expandable braid and comprises female/male element 732 of a locking mechanism, which is preferably reversible. Everting valve 720 comprises valve leaflets 726 and everting segment 728. Everting valve 720 further comprises posts 722 to which valve leaflets 726 are attached to provide commissure support. Posts 722, which are non-expandable and non-collapsible, comprise opposite male/female elements 723 of locking mechanism comprising eyelets. In the delivery configuration of FIG. 41A, anchor 730 may extend distally far enough to just overlap the proximal-most section of valve 720.

Delivery system 750 is similar to previously described delivery system 100′ and includes multi-lumen catheter 180. As with previous embodiments, delivery system 750 facilitates dynamic repositioning and/or retrieval of apparatus 700 after partial or full deployment of the apparatus, e.g., right up until the apparatus is separated from the delivery system.

As seen in FIG. 41A, wires 50 pass from the multi-lumen catheter 180 through the female/male locking mechanism 732, which is associated with anchor 730. Wires 50 then further pass through female/male locking mechanism 723, which is at the proximal end of posts 722. Preferably, a double strand of each wire 50 is provided to facilitate decoupling of wires 50 from valve 720 and anchor 730 in the manner described previously. When wires 50 are pulled proximally into the multi lumen catheter 180, posts 722 move proximally within anchor 730, and the female/male element 723 interacts with female/male element 732 of anchor 730. In this embodiment, when element 723 is male, then element 732 is female, and vice versa.

Thus, valve 720 and anchor 730 are entirely decoupled from one another in the delivery configuration. Wires 50 are configured to approximate the telescoped valve and anchor, as well as to actuate locking mechanism 740 and contribute to foreshortening of anchor 730. By separating valve 720 and anchor 730 within lumen 112′ of sheath 110′, a delivery profile of apparatus 700 may be reduced.

In FIG. 41A, apparatus 700 is endovascularly advanced into position with valve 720 and anchor 730 spaced from one another within lumen 112′ of sheath 110′ of delivery system 750. Substantially all of valve 720 and its supporting posts 722 are disposed distal to the anchor during delivery. As seen in FIG. 41B, to evert valve 720, sheath 110′ is pulled proximally around anchor 730.

Next, in FIG. 41C, to approximate anchor 730 and valve 720, the elongated braid of anchor 730 is pushed distally to the base of posts 722 using tubes 60 maintained in association with anchor 730 by wire 62. Anchor 730 will engage with the distal end of posts 722—an anchor engagement feature 729. In some embodiments, as illustrated in FIG. 41C, wires 550 re-enter sheath 110′ proximal to the distal end of the multi-lumen catheter 180.

In FIG. 41D, the multi-lumen catheter 180 is held steady, while wires 50 are pulled proximally. This allows the foreshortening of anchor 730 and the engagement of the male and female elements of locking mechanism of 740. Foreshortening friction locks segment 728 of valve 720 against valve annulus An/leaflets L, thereby properly seating the valve within anchor 730. Foreshortening also completes expansion of anchor 730 and actuates locking mechanism 740, which maintains such expansion of the anchor. Delivery system 750 then may be decoupled from valve 720 and anchor 730, thereby completing deployment of apparatus 700. Normal blood flow between left ventricle LV and aorta A thereafter is regulated by replacement valve 720.

With reference now to FIG. 42, yet another alternative embodiment of everting apparatus in accordance with the present invention is described, wherein the replacement valve leaflets evert and wrap about the distal region of the anchor. Apparatus 800 comprises everting replacement valve 820 and expandable anchor 830. Valve 820 comprises posts 822, to which valve leaflets 826 are attached. The valve further comprises everting segment 828. Proximal regions 823 of posts 822 are rotatably coupled to a distal region of anchor 830, while distal regions 824 of the posts are coupled to control wires 50.

In the delivery configuration of FIG. 42A, posts 822 (and, thus, valve leaflets 826) and everting segment 828 of replacement valve 820 are disposed distal of anchor 830. FIG. 42B illustrates deployment of apparatus 800, whereby tubes 60/wires 62 (see, e.g., FIG. 41) are actuated in conjunction with control wires 50 to actively foreshorten anchor 830 and rotate posts 822 into position within the lumen of anchor 830, thereby everting valve leaflets 826 into position within the anchor. Furthermore, eversion wires 550 are actuated to evert segment 828 and wrap the segment about the exterior of anchor 830. Locks 840 maintain expansion and foreshortening of anchor 830.

Referring to FIG. 43, an everting embodiment of the present invention is described wherein a portion of the locking mechanism configured to maintain expansion of the anchor is coupled to the everting segment of the replacement valve instead of, or in addition to, the anchor posts and anchor posts P are only loosely associated with the anchor 930. Apparatus 900 comprises replacement valve 920 and anchor 930. Everting segment 928 of the replacement valve comprises male elements 942 of locks 940, while anchor 930 comprises female elements 944 of locks 940. Upon deployment of apparatus 900 from the delivery configuration of FIG. 43A to the deployed configuration of FIG. 43B, segment 928 of replacement valve 920 everts to wrap about the exterior of anchor 930, which is actively foreshortened during expansion. Locks 940 maintain anchor expansion.

With reference to FIG. 44, another telescoping embodiment of the present invention is described wherein the replacement valve comprises a U-shaped frame configured to receive the anchor. Optionally, the valve may comprise an everting segment that everts about the frame and/or the anchor during deployment. Apparatus 1000 comprises replacement valve 1020 and expandable anchor 1030. Replacement valve 1020 comprises frame 1022, leaflets 1026 and optional everting segment 1028.

Valve 1020 and anchor 1030 are configured for relative movement, such that the valve and anchor may be telescoped and spaced apart during delivery, thereby reducing a delivery profile of apparatus 1000, but may be approximated during deployment. Everting segment 1028 of valve 1020 optionally may be disposed distal of valve frame 1022 during delivery, thereby further reducing a delivery profile of apparatus 1000, then everted during deployment.

As seen in FIG. 44A, the U-shape of valve frame 1022 preferably tilts leaflets 1026 of replacement valve 1020 slightly inward relative to blood flow through apparatus 1000. As seen in FIG. 44B, valve frame 1022 optionally may comprise a symmetric U-shape, which captures anchor 1030 on both sides in the deployed configuration. Frame 1022 may comprise lock 1040 that closes the frame's U-shape into an elliptical shape in the deployed configuration, thereby maintaining expansion of anchor 1030.

Prior to implantation of one of the replacement valves described above, it may be desirable to perform a valvuloplasty on the diseased valve by inserting a balloon into the valve and expanding it using saline mixed with a contrast agent. In addition to preparing the valve site for implant, fluoroscopic viewing of the valvuloplasty will help determine the appropriate size of replacement valve implant to use.

Claims

1. A prosthetic heart valve, comprising: an expandable stent having a stent frame, an inflow end region and an outflow end region;wherein the expandable stent is adapted to shift between a first configuration and a second configuration, the first configuration being adapted for delivery of the expandable stent within a delivery device to the native heart valve of the patient, the second configuration being a deployed configuration where the expandable stent is expanded at the native heart valve of the patient;a plurality of leaflets coupled to the expandable stent, the plurality of leaflets defining a valve assembly that is adapted to shift between an open configuration and a closed configuration;a sealing member coupled to the stent frame,wherein the sealing member includes one or more sacs open to blood flow,wherein the sealing member is adapted to shift between a first configuration and an expanded configuration; andwherein when the stent is in the second configuration, the sealing member adapts to adjacent anatomical regions and conforms with the adjacent anatomical regions such that a fluid tight seal is formed between an outer surface of the expandable stent and the adjacent anatomical regions and so that paravalvular leakage is substantially prevented.
2. The prosthetic heart valve of claim 1, wherein the expandable stent includes a nickel-titanium alloy.
3. The prosthetic heart valve of claim 1, wherein the expandable stent includes a cobalt-chromium alloy.
4. The prosthetic heart valve of claim 1, wherein the sealing member includes a fabric.
5. The prosthetic heart valve of claim 1, wherein the sealing member includes one or more flaps.
6. The prosthetic heart valve of claim 1, wherein the sealing member is disposed along the outer surface of the expandable stent.
7. A prosthetic heart valve, comprising: an expandable stent frame having an outer surface, the expandable stent frame is adapted to shift between a first configuration and a second configuration, the first configuration being adapted for delivery of the expandable stent within a delivery device to the native heart valve of the patient, the second configuration being a deployed configuration where the expandable stent is expanded at the native heart valve of the patient;a plurality of leaflets coupled to the stent frame;a sealing member coupled to the expandable stent,wherein the sealing member includes one or more sacs open to blood flow,the sealing member being adapted to shift between a first configuration and an expanded configuration;wherein at least a portion of the sealing member is disposed along an outer surface of the stent frame; andwherein the sealing member includes one or more sacs when in the expanded configuration.
8. The prosthetic heart valve of claim 7, wherein the stent frame includes a nickel-titanium alloy.
9. The prosthetic heart valve of claim 7, wherein the stent frame includes a cobalt-chromium alloy.
10. The prosthetic heart valve of claim 7, wherein the sealing member includes a fabric.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. application Ser. No. 15/658,255, filed Jul. 24, 2017, which is a continuation of U.S. application Ser. No. 14/873,462, filed Oct. 2, 2015, now U.S. Pat. No. 9,744,035, which is a continuation of U.S. application Ser. No. 14/669,738, filed Mar. 26, 2015, now abandoned, which is a continuation of U.S. application Ser. No. 12/492,512, filed Jun. 26, 2009, now U.S. Pat. No. 8,992,608; which is a divisional of U.S. application Ser. No. 12/269,213 filed Nov. 12, 2008, now U.S. Pat. No. 8,668,733; which application is a continuation of U.S. application Ser. No. 10/870,340, filed Jun. 16, 2004, now U.S. Pat. No. 7,780,725, the disclosures of which are incorporated by reference in their entirety.

US Referenced Citations (807)

Number	Name	Date	Kind
15192	Peale	Jun 1856	A
2682057	Lord	Jun 1954	A
2701559	Cooper	Feb 1955	A
2832078	Williams	Apr 1958	A
3099016	Edwards	Jul 1963	A
3113586	Edmark, Jr.	Dec 1963	A
3130418	Head et al.	Apr 1964	A
3143742	Cromie	Aug 1964	A
3334629	Cohn	Aug 1967	A
3367364	Cruz, Jr. et al.	Feb 1968	A
3409013	Berry	Nov 1968	A
3445916	Schulte	May 1969	A
3540431	Mobin-Uddin	Nov 1970	A
3548417	Kischer et al.	Dec 1970	A
3570014	Hancock	Mar 1971	A
3587115	Shiley	Jun 1971	A
3592184	Watkins et al.	Jul 1971	A
3628535	Ostrowsky et al.	Dec 1971	A
3642004	Osthagen et al.	Feb 1972	A
3657744	Ersek	Apr 1972	A
3671979	Moulopoulos	Jun 1972	A
3714671	Edwards et al.	Feb 1973	A
3755823	Hancock	Sep 1973	A
3795246	Sturgeon	Mar 1974	A
3839741	Haller	Oct 1974	A
3868956	Alfidi et al.	Mar 1975	A
3874388	King et al.	Apr 1975	A
3997923	Possis	Dec 1976	A
4035849	Angell et al.	Jul 1977	A
4056854	Boretos et al.	Nov 1977	A
4106129	Carpentier et al.	Aug 1978	A
4222126	Boretos et al.	Sep 1980	A
4233690	Akins	Nov 1980	A
4265694	Boretos et al.	May 1981	A
4291420	Reul	Sep 1981	A
4297749	Davis et al.	Nov 1981	A
4323358	Lentz et al.	Apr 1982	A
4326306	Poler	Apr 1982	A
4339831	Johnson	Jul 1982	A
4343048	Ross et al.	Aug 1982	A
4345340	Rosen	Aug 1982	A
4373216	Klawitter	Feb 1983	A
4406022	Roy	Sep 1983	A
4423809	Mazzocco	Jan 1984	A
4425908	Simon	Jan 1984	A
4470157	Love	Sep 1984	A
4484579	Meno et al.	Nov 1984	A
4501030	Lane	Feb 1985	A
4531943	Van Tassel et al.	Jul 1985	A
4535483	Klawitter et al.	Aug 1985	A
4574803	Storz	Mar 1986	A
4580568	Gianturco	Apr 1986	A
4592340	Boyles	Jun 1986	A
4602911	Ahmadi et al.	Jul 1986	A
4605407	Black et al.	Aug 1986	A
4610688	Silvestrini et al.	Sep 1986	A
4612011	Kautzky	Sep 1986	A
4617932	Kornberg	Oct 1986	A
4643732	Pietsch et al.	Feb 1987	A
4647283	Carpentier et al.	Mar 1987	A
4648881	Carpentier et al.	Mar 1987	A
4655218	Kulik et al.	Apr 1987	A
4655771	Wallsten	Apr 1987	A
4662885	Dipisa, Jr.	May 1987	A
4665906	Jervis	May 1987	A
4680031	Alonso	Jul 1987	A
4692164	Dzemeshkevich et al.	Sep 1987	A
4705516	Barone et al.	Nov 1987	A
4710192	Liotta et al.	Dec 1987	A
4733665	Palmaz	Mar 1988	A
4755181	Igoe	Jul 1988	A
4759758	Gabbay	Jul 1988	A
4777951	Cribier et al.	Oct 1988	A
4787899	Lazarus	Nov 1988	A
4787901	Baykut	Nov 1988	A
4796629	Grayzel	Jan 1989	A
4819751	Shimada et al.	Apr 1989	A
4829990	Thuroff et al.	May 1989	A
4834755	Silvestrini et al.	May 1989	A
4851001	Taheri	Jul 1989	A
4856516	Hillstead	Aug 1989	A
4865600	Carpentier et al.	Sep 1989	A
4872874	Taheri	Oct 1989	A
4873978	Ginsburg	Oct 1989	A
4878495	Grayzel	Nov 1989	A
4878906	Lindemann et al.	Nov 1989	A
4883458	Shiber	Nov 1989	A
4885005	Nashef et al.	Dec 1989	A
4909252	Goldberger	Mar 1990	A
4917102	Miller et al.	Apr 1990	A
4922905	Strecker	May 1990	A
4927426	Dretler	May 1990	A
4954126	Wallsten	Sep 1990	A
4966604	Reiss	Oct 1990	A
4969890	Sugita et al.	Nov 1990	A
4979939	Shiber	Dec 1990	A
4986830	Owens et al.	Jan 1991	A
4994077	Dobben	Feb 1991	A
5002556	Ishida et al.	Mar 1991	A
5002559	Tower	Mar 1991	A
5007896	Shiber	Apr 1991	A
5026366	Leckrone	Jun 1991	A
5032128	Alonso	Jul 1991	A
5037434	Lane	Aug 1991	A
5047041	Samuels	Sep 1991	A
5064435	Porter	Nov 1991	A
5080668	Bolz et al.	Jan 1992	A
5085635	Cragg	Feb 1992	A
5089015	Ross	Feb 1992	A
5132473	Furutaka et al.	Jul 1992	A
5141494	Danforth et al.	Aug 1992	A
5152771	Sabbaghian et al.	Oct 1992	A
5159937	Tremulis	Nov 1992	A
5161547	Tower	Nov 1992	A
5163953	Vince	Nov 1992	A
5167628	Boyles	Dec 1992	A
5209741	Spaeth	May 1993	A
5215541	Nashef et al.	Jun 1993	A
5217483	Tower	Jun 1993	A
5238004	Sahatjian et al.	Aug 1993	A
5258023	Reger	Nov 1993	A
5258042	Mehta	Nov 1993	A
5282847	Trescony et al.	Feb 1994	A
5295958	Shturman	Mar 1994	A
5332402	Teitelbaum	Jul 1994	A
5336258	Quintero et al.	Aug 1994	A
5350398	Pavcnik et al.	Sep 1994	A
5360444	Kusuhara	Nov 1994	A
5370685	Stevens	Dec 1994	A
5389106	Tower	Feb 1995	A
5397351	Pavcnik et al.	Mar 1995	A
5409019	Wilk	Apr 1995	A
5411552	Andersen et al.	May 1995	A
5425762	Muller	Jun 1995	A
5431676	Dubrul et al.	Jul 1995	A
5443446	Shturman	Aug 1995	A
5443449	Buelna	Aug 1995	A
5443477	Marin et al.	Aug 1995	A
5443495	Buscemi et al.	Aug 1995	A
5443499	Schmitt	Aug 1995	A
5476506	Lunn	Dec 1995	A
5476510	Eberhardt et al.	Dec 1995	A
5480423	Ravenscroft et al.	Jan 1996	A
5480424	Cox	Jan 1996	A
5500014	Quijano et al.	Mar 1996	A
5507767	Maeda et al.	Apr 1996	A
5534007	St. Germain et al.	Jul 1996	A
5545133	Burns et al.	Aug 1996	A
5545209	Roberts et al.	Aug 1996	A
5545211	An et al.	Aug 1996	A
5545214	Stevens	Aug 1996	A
5549665	Vesely et al.	Aug 1996	A
5554185	Block et al.	Sep 1996	A
5571175	Vanney et al.	Nov 1996	A
5571215	Sterman et al.	Nov 1996	A
5573520	Schwartz et al.	Nov 1996	A
5575818	Pinchuk	Nov 1996	A
5591185	Kilmer et al.	Jan 1997	A
5591195	Taheri et al.	Jan 1997	A
5607464	Trescony et al.	Mar 1997	A
5609626	Quijano et al.	Mar 1997	A
5645559	Hachtman et al.	Jul 1997	A
5662671	Barbut et al.	Sep 1997	A
5667523	Bynon et al.	Sep 1997	A
5674277	Freitag	Oct 1997	A
5693083	Baker et al.	Dec 1997	A
5693310	Gries et al.	Dec 1997	A
5695498	Tower	Dec 1997	A
5709713	Evans et al.	Jan 1998	A
5713951	Garrison et al.	Feb 1998	A
5713953	Vallana et al.	Feb 1998	A
5716370	Williamson, IV et al.	Feb 1998	A
5716417	Girard et al.	Feb 1998	A
5720391	Dohm et al.	Feb 1998	A
5725549	Lam	Mar 1998	A
5728068	Leone et al.	Mar 1998	A
5733325	Robinson et al.	Mar 1998	A
5735842	Krueger et al.	Apr 1998	A
5749890	Shaknovich	May 1998	A
5755783	Stobie et al.	May 1998	A
5756476	Epstein et al.	May 1998	A
5769812	Stevens et al.	Jun 1998	A
5772609	Nguyen et al.	Jun 1998	A
5800456	Maeda et al.	Sep 1998	A
5800531	Cosgrove et al.	Sep 1998	A
5807405	Vanney et al.	Sep 1998	A
5817126	Imran	Oct 1998	A
5824041	Lenker et al.	Oct 1998	A
5824043	Cottone, Jr.	Oct 1998	A
5824053	Khosravi et al.	Oct 1998	A
5824055	Spiridigliozzi et al.	Oct 1998	A
5824056	Rosenberg	Oct 1998	A
5824064	Taheri	Oct 1998	A
5840081	Andersen et al.	Nov 1998	A
5843158	Lenker et al.	Dec 1998	A
5855597	Jayaraman	Jan 1999	A
5855601	Bessler et al.	Jan 1999	A
5855602	Angell	Jan 1999	A
5860966	Tower	Jan 1999	A
5861024	Rashidi	Jan 1999	A
5861028	Angell	Jan 1999	A
5868783	Tower	Feb 1999	A
5876419	Carpenter et al.	Mar 1999	A
5876448	Thompson et al.	Mar 1999	A
5885228	Rosenman et al.	Mar 1999	A
5888201	Stinson et al.	Mar 1999	A
5891191	Stinson	Apr 1999	A
5895399	Barbut et al.	Apr 1999	A
5906619	Olson et al.	May 1999	A
5907893	Zadno-Azizi et al.	Jun 1999	A
5910154	Tsugita et al.	Jun 1999	A
5911734	Tsugita et al.	Jun 1999	A
5925063	Khosravi	Jul 1999	A
5944738	Amplatz et al.	Aug 1999	A
5954766	Zadno-Azizi et al.	Sep 1999	A
5957949	Leonhardt et al.	Sep 1999	A
5968070	Bley et al.	Oct 1999	A
5984957	Laptewicz, Jr. et al.	Nov 1999	A
5984959	Robertson et al.	Nov 1999	A
5993469	McKenzie et al.	Nov 1999	A
5997557	Barbut et al.	Dec 1999	A
6010522	Barbut et al.	Jan 2000	A
6022370	Tower	Feb 2000	A
6027520	Tsugita et al.	Feb 2000	A
6027525	Suh et al.	Feb 2000	A
6042598	Tsugita et al.	Mar 2000	A
6042607	Williamson, IV et al.	Mar 2000	A
6051014	Jang	Apr 2000	A
6059827	Fenton, Jr.	May 2000	A
6074418	Buchanan et al.	Jun 2000	A
6093203	Uflacker	Jul 2000	A
6096074	Pedros	Aug 2000	A
6123723	Konya et al.	Sep 2000	A
6132473	Williams et al.	Oct 2000	A
6139510	Palermo	Oct 2000	A
6142987	Tsugita	Nov 2000	A
6146366	Schachar	Nov 2000	A
6162245	Jayaraman	Dec 2000	A
6165200	Tsugita et al.	Dec 2000	A
6165209	Patterson et al.	Dec 2000	A
6168579	Tsugita	Jan 2001	B1
6168614	Andersen et al.	Jan 2001	B1
6171327	Daniel et al.	Jan 2001	B1
6171335	Wheatley et al.	Jan 2001	B1
6179859	Bates et al.	Jan 2001	B1
6187016	Hedges et al.	Feb 2001	B1
6197053	Cosgrove et al.	Mar 2001	B1
6200336	Pavcnik et al.	Mar 2001	B1
6214036	Letendre et al.	Apr 2001	B1
6221006	Dubrul et al.	Apr 2001	B1
6221091	Khosravi	Apr 2001	B1
6221096	Aiba et al.	Apr 2001	B1
6221100	Strecker	Apr 2001	B1
6231544	Tsugita et al.	May 2001	B1
6231551	Barbut	May 2001	B1
6241757	An et al.	Jun 2001	B1
6245102	Jayaraman	Jun 2001	B1
6251135	Stinson et al.	Jun 2001	B1
6258114	Konya et al.	Jul 2001	B1
6258115	Dubrul	Jul 2001	B1
6258120	McKenzie et al.	Jul 2001	B1
6258129	Dybdal et al.	Jul 2001	B1
6267783	Letendre et al.	Jul 2001	B1
6270513	Tsugita et al.	Aug 2001	B1
6277555	Duran et al.	Aug 2001	B1
6299637	Shaolian et al.	Oct 2001	B1
6302906	Goicoechea et al.	Oct 2001	B1
6309417	Spence et al.	Oct 2001	B1
6319281	Patel	Nov 2001	B1
6327772	Zadno-Azizi et al.	Dec 2001	B1
6336934	Gilson et al.	Jan 2002	B1
6336937	Vonesh et al.	Jan 2002	B1
6338735	Stevens	Jan 2002	B1
6346116	Brooks et al.	Feb 2002	B1
6348063	Yassour et al.	Feb 2002	B1
6352554	De Paulis	Mar 2002	B2
6352708	Duran et al.	Mar 2002	B1
6361545	Macoviak et al.	Mar 2002	B1
6363938	Saadat et al.	Apr 2002	B2
6364895	Greenhalgh	Apr 2002	B1
6371970	Khosravi et al.	Apr 2002	B1
6371983	Lane	Apr 2002	B1
6379383	Palmaz et al.	Apr 2002	B1
6398807	Chouinard et al.	Jun 2002	B1
6402736	Brown et al.	Jun 2002	B1
6409750	Hyodoh et al.	Jun 2002	B1
6416510	Altman et al.	Jul 2002	B1
6425916	Garrison et al.	Jul 2002	B1
6440164	DiMatteo et al.	Aug 2002	B1
6454799	Schreck	Sep 2002	B1
6458153	Bailey et al.	Oct 2002	B1
6461382	Cao	Oct 2002	B1
6468303	Amplatz et al.	Oct 2002	B1
6468660	Ogle et al.	Oct 2002	B2
6475239	Campbell et al.	Nov 2002	B1
6482228	Norred	Nov 2002	B1
6485501	Green	Nov 2002	B1
6485502	Don Michael et al.	Nov 2002	B2
6488704	Connelly et al.	Dec 2002	B1
6494909	Greenhalgh	Dec 2002	B2
6503272	Duerig et al.	Jan 2003	B2
6508803	Horikawa et al.	Jan 2003	B1
6508833	Pavcnik et al.	Jan 2003	B2
6527800	McGuckin, Jr. et al.	Mar 2003	B1
6530949	Konya et al.	Mar 2003	B2
6530952	Vesely	Mar 2003	B2
6537297	Tsugita et al.	Mar 2003	B2
6540768	Diaz et al.	Apr 2003	B1
6562058	Seguin et al.	May 2003	B2
6569196	Vesely	May 2003	B1
6572643	Gharibadeh	Jun 2003	B1
6585766	Huynh et al.	Jul 2003	B1
6592546	Barbut et al.	Jul 2003	B1
6592614	Lenker et al.	Jul 2003	B2
6605112	Moll et al.	Aug 2003	B1
6610077	Hancock et al.	Aug 2003	B1
6616682	Joergensen et al.	Sep 2003	B2
6622604	Chouinard et al.	Sep 2003	B1
6623518	Thompson et al.	Sep 2003	B2
6623521	Steinke et al.	Sep 2003	B2
6632243	Zadno-Azizi et al.	Oct 2003	B1
6635068	Dubrul et al.	Oct 2003	B1
6635079	Unsworth et al.	Oct 2003	B2
6652571	White et al.	Nov 2003	B1
6652578	Bailey et al.	Nov 2003	B2
6663588	DuBois et al.	Dec 2003	B2
6663663	Kim et al.	Dec 2003	B2
6669724	Park et al.	Dec 2003	B2
6673089	Yassour et al.	Jan 2004	B1
6673109	Cox	Jan 2004	B2
6676668	Mercereau et al.	Jan 2004	B2
6676692	Rabkin et al.	Jan 2004	B2
6676698	McGuckin, Jr. et al.	Jan 2004	B2
6682543	Barbut et al.	Jan 2004	B2
6682558	Tu et al.	Jan 2004	B2
6682559	Myers et al.	Jan 2004	B2
6685739	DiMatteo et al.	Feb 2004	B2
6689144	Gerberding	Feb 2004	B2
6689164	Seguin	Feb 2004	B1
6692512	Jang	Feb 2004	B2
6695864	Macoviak et al.	Feb 2004	B2
6695865	Boyle et al.	Feb 2004	B2
6702851	Chinn et al.	Mar 2004	B1
6712842	Gifford, III et al.	Mar 2004	B1
6712843	Elliott	Mar 2004	B2
6714842	Ito	Mar 2004	B1
6719789	Cox	Apr 2004	B2
6723116	Taheri	Apr 2004	B2
6730118	Spenser et al.	May 2004	B2
6730377	Wang	May 2004	B2
6733525	Yang et al.	May 2004	B2
6736846	Cox	May 2004	B2
6752828	Thornton	Jun 2004	B2
6755854	Gillick et al.	Jun 2004	B2
6758855	Fulton, III et al.	Jul 2004	B2
6764503	Ishimaru	Jul 2004	B1
6764509	Chinn et al.	Jul 2004	B2
6767345	St. Germain et al.	Jul 2004	B2
6769434	Liddicoat et al.	Aug 2004	B2
6773454	Wholey et al.	Aug 2004	B2
6776791	Stallings et al.	Aug 2004	B1
6786925	Schoon et al.	Sep 2004	B1
6790229	Berreklouw	Sep 2004	B1
6790230	Beyersdorf et al.	Sep 2004	B2
6790237	Stinson	Sep 2004	B2
6792979	Konya et al.	Sep 2004	B2
6797002	Spence et al.	Sep 2004	B2
6814746	Thompson et al.	Nov 2004	B2
6821297	Snyders	Nov 2004	B2
6830585	Artof et al.	Dec 2004	B1
6837901	Rabkin et al.	Jan 2005	B2
6840957	DiMatteo et al.	Jan 2005	B2
6843802	Villalobos et al.	Jan 2005	B1
6849085	Marton	Feb 2005	B2
6863668	Gillespie et al.	Mar 2005	B2
6866650	Stevens et al.	Mar 2005	B2
6866669	Buzzard et al.	Mar 2005	B2
6872223	Roberts et al.	Mar 2005	B2
6872226	Cali et al.	Mar 2005	B2
6875231	Anduiza et al.	Apr 2005	B2
6881220	Edwin et al.	Apr 2005	B2
6887266	Williams et al.	May 2005	B2
6890340	Duane	May 2005	B2
6893459	Macoviak	May 2005	B1
6893460	Spenser et al.	May 2005	B2
6905743	Chen et al.	Jun 2005	B1
6908481	Cribier	Jun 2005	B2
6911036	Douk et al.	Jun 2005	B2
6911043	Myers et al.	Jun 2005	B2
6936058	Forde et al.	Aug 2005	B2
6936067	Buchanan	Aug 2005	B2
6939352	Buzzard et al.	Sep 2005	B2
6951571	Srivastava	Oct 2005	B1
6953332	Kurk et al.	Oct 2005	B1
6964673	Tsugita et al.	Nov 2005	B2
6969395	Eskur	Nov 2005	B2
6972025	WasDyke	Dec 2005	B2
6974464	Quijano et al.	Dec 2005	B2
6974474	Pavcnik et al.	Dec 2005	B2
6974476	McGuckin, Jr. et al.	Dec 2005	B2
6979350	Moll et al.	Dec 2005	B2
6984242	Campbell et al.	Jan 2006	B2
6989027	Allen et al.	Jan 2006	B2
7004176	Lau	Feb 2006	B2
7011681	Vesely	Mar 2006	B2
7018406	Seguin et al.	Mar 2006	B2
7025791	Levine et al.	Apr 2006	B2
7037331	Mitelberg et al.	May 2006	B2
7041132	Quijano et al.	May 2006	B2
7097658	Oktay	Aug 2006	B2
7122020	Mogul	Oct 2006	B2
7125418	Duran et al.	Oct 2006	B2
7141063	White et al.	Nov 2006	B2
7166097	Barbut	Jan 2007	B2
7175653	Gaber	Feb 2007	B2
7175654	Bonsignore et al.	Feb 2007	B2
7175656	Khairkhahan	Feb 2007	B2
7189258	Johnson et al.	Mar 2007	B2
7191018	Gielen et al.	Mar 2007	B2
7201772	Schwammenthal et al.	Apr 2007	B2
7235093	Gregorich	Jun 2007	B2
7252682	Seguin	Aug 2007	B2
7258696	Rabkin et al.	Aug 2007	B2
7267686	DiMatteo et al.	Sep 2007	B2
7276078	Spenser et al.	Oct 2007	B2
7322932	Xie et al.	Jan 2008	B2
7326236	Andreas et al.	Feb 2008	B2
7329279	Haug et al.	Feb 2008	B2
7374560	Ressemann et al.	May 2008	B2
7381219	Salahieh et al.	Jun 2008	B2
7381220	Macoviak et al.	Jun 2008	B2
7399315	Iobbi	Jul 2008	B2
7445631	Salahieh et al.	Nov 2008	B2
7470285	Nugent et al.	Dec 2008	B2
7491232	Bolduc et al.	Feb 2009	B2
7510574	Lê et al.	Mar 2009	B2
7524330	Berreklouw	Apr 2009	B2
7530995	Quijano et al.	May 2009	B2
7544206	Cohn	Jun 2009	B2
7622276	Cunanan et al.	Nov 2009	B2
7628803	Pavcnik et al.	Dec 2009	B2
7632298	Hijlkema et al.	Dec 2009	B2
7674282	Wu et al.	Mar 2010	B2
7712606	Salahieh et al.	May 2010	B2
7722638	Deyette, Jr. et al.	May 2010	B2
7722662	Steinke et al.	May 2010	B2
7722666	Lafontaine	May 2010	B2
7736388	Goldfarb et al.	Jun 2010	B2
7748389	Salahieh et al.	Jul 2010	B2
7758625	Wu et al.	Jul 2010	B2
7780725	Haug et al.	Aug 2010	B2
7799065	Pappas	Sep 2010	B2
7803185	Gabbay	Sep 2010	B2
7824442	Salahieh et al.	Nov 2010	B2
7824443	Salahieh et al.	Nov 2010	B2
7833262	McGuckin, Jr. et al.	Nov 2010	B2
7846204	Letac et al.	Dec 2010	B2
7892292	Stack et al.	Feb 2011	B2
7918880	Austin	Apr 2011	B2
7938851	Olson et al.	May 2011	B2
7959666	Salahieh et al.	Jun 2011	B2
7959672	Salahieh et al.	Jun 2011	B2
7988724	Salahieh et al.	Aug 2011	B2
8048153	Salahieh et al.	Nov 2011	B2
8052749	Salahieh et al.	Nov 2011	B2
8136659	Salahieh et al.	Mar 2012	B2
8157853	Laske et al.	Apr 2012	B2
8182528	Salahieh et al.	May 2012	B2
8192351	Fishler et al.	Jun 2012	B2
8226710	Nguyen et al.	Jul 2012	B2
8231670	Salahieh et al.	Jul 2012	B2
8236049	Rowe et al.	Aug 2012	B2
8246678	Salahieh et al.	Aug 2012	B2
8252051	Chau et al.	Aug 2012	B2
8252052	Salahieh et al.	Aug 2012	B2
8287584	Salahieh et al.	Oct 2012	B2
8308798	Pintor et al.	Nov 2012	B2
8323335	Rowe et al.	Dec 2012	B2
8328868	Paul et al.	Dec 2012	B2
8343213	Salahieh et al.	Jan 2013	B2
8376865	Forster et al.	Feb 2013	B2
8377117	Keidar et al.	Feb 2013	B2
8398708	Meiri et al.	Mar 2013	B2
8579962	Salahieh et al.	Nov 2013	B2
8603160	Salahieh et al.	Dec 2013	B2
8617236	Paul et al.	Dec 2013	B2
8623074	Ryan	Jan 2014	B2
8623076	Salahieh et al.	Jan 2014	B2
8623078	Salahieh et al.	Jan 2014	B2
8668733	Haug et al.	Mar 2014	B2
8828078	Salahieh et al.	Sep 2014	B2
8840662	Salahieh et al.	Sep 2014	B2
8840663	Salahieh et al.	Sep 2014	B2
8858620	Salahieh et al.	Oct 2014	B2
8992608	Haug	Mar 2015	B2
20010002445	Vesely	May 2001	A1
20010007956	Letac et al.	Jul 2001	A1
20010010017	Letac et al.	Jul 2001	A1
20010021872	Bailey et al.	Sep 2001	A1
20010025196	Chinn et al.	Sep 2001	A1
20010032013	Marton	Oct 2001	A1
20010039450	Pavcnik et al.	Nov 2001	A1
20010041928	Pavcnik et al.	Nov 2001	A1
20010041930	Globerman et al.	Nov 2001	A1
20010044634	Don Michael et al.	Nov 2001	A1
20010044652	Moore	Nov 2001	A1
20010044656	Williamson, IV et al.	Nov 2001	A1
20020002396	Fulkerson	Jan 2002	A1
20020010489	Grayzel et al.	Jan 2002	A1
20020026233	Shaknovich	Feb 2002	A1
20020029014	Jayaraman	Mar 2002	A1
20020029981	Nigam	Mar 2002	A1
20020032480	Spence et al.	Mar 2002	A1
20020032481	Gabbay	Mar 2002	A1
20020042651	Liddicoat et al.	Apr 2002	A1
20020052651	Myers et al.	May 2002	A1
20020055767	Forde et al.	May 2002	A1
20020055769	Wang	May 2002	A1
20020058995	Stevens	May 2002	A1
20020077696	Zadno-Azizi et al.	Jun 2002	A1
20020082609	Green	Jun 2002	A1
20020095173	Mazzocchi et al.	Jul 2002	A1
20020095209	Zadno-Azizi et al.	Jul 2002	A1
20020111674	Chouinard et al.	Aug 2002	A1
20020120328	Pathak et al.	Aug 2002	A1
20020123802	Snyders	Sep 2002	A1
20020138138	Yang	Sep 2002	A1
20020151970	Garrison et al.	Oct 2002	A1
20020161390	Mouw	Oct 2002	A1
20020161392	Dubrul	Oct 2002	A1
20020161394	Macoviak et al.	Oct 2002	A1
20020165576	Boyle et al.	Nov 2002	A1
20020177766	Mogul	Nov 2002	A1
20020183781	Casey et al.	Dec 2002	A1
20020188341	Elliott	Dec 2002	A1
20020188344	Bolea et al.	Dec 2002	A1
20020193871	Beyersdorf et al.	Dec 2002	A1
20030014104	Cribier	Jan 2003	A1
20030023303	Palmaz et al.	Jan 2003	A1
20030028247	Cali	Feb 2003	A1
20030036791	Philipp et al.	Feb 2003	A1
20030040736	Stevens et al.	Feb 2003	A1
20030040771	Hyodoh et al.	Feb 2003	A1
20030040772	Hyodoh et al.	Feb 2003	A1
20030040791	Oktay	Feb 2003	A1
20030040792	Gabbay	Feb 2003	A1
20030050694	Yang et al.	Mar 2003	A1
20030055495	Pease et al.	Mar 2003	A1
20030057156	Peterson et al.	Mar 2003	A1
20030060844	Borillo et al.	Mar 2003	A1
20030069492	Abrams et al.	Apr 2003	A1
20030069646	Stinson	Apr 2003	A1
20030070944	Nigam	Apr 2003	A1
20030100918	Duane	May 2003	A1
20030100919	Hopkins et al.	May 2003	A1
20030109924	Cribier	Jun 2003	A1
20030109930	Bluni et al.	Jun 2003	A1
20030114912	Sequin et al.	Jun 2003	A1
20030114913	Spenser et al.	Jun 2003	A1
20030125795	Pavcnik et al.	Jul 2003	A1
20030130729	Paniagua et al.	Jul 2003	A1
20030130746	Ashworth	Jul 2003	A1
20030135257	Taheri	Jul 2003	A1
20030144732	Cosgrove et al.	Jul 2003	A1
20030149475	Hyodoh et al.	Aug 2003	A1
20030149476	Damm et al.	Aug 2003	A1
20030149478	Figulla et al.	Aug 2003	A1
20030153974	Spenser et al.	Aug 2003	A1
20030171803	Shimon	Sep 2003	A1
20030176884	Berrada et al.	Sep 2003	A1
20030181850	Diamond et al.	Sep 2003	A1
20030187495	Cully et al.	Oct 2003	A1
20030191516	Weldon et al.	Oct 2003	A1
20030195609	Berenstein et al.	Oct 2003	A1
20030199759	Richard	Oct 2003	A1
20030199913	Dubrul et al.	Oct 2003	A1
20030199971	Tower et al.	Oct 2003	A1
20030199972	Zadno-Azizi et al.	Oct 2003	A1
20030208224	Broome	Nov 2003	A1
20030212429	Keegan et al.	Nov 2003	A1
20030212452	Zadno-Azizi et al.	Nov 2003	A1
20030212454	Scott et al.	Nov 2003	A1
20030216774	Larson	Nov 2003	A1
20030225445	Derus et al.	Dec 2003	A1
20030229390	Ashton et al.	Dec 2003	A1
20030233117	Adams et al.	Dec 2003	A1
20040019374	Hojeibane et al.	Jan 2004	A1
20040034411	Quijano et al.	Feb 2004	A1
20040039436	Spenser et al.	Feb 2004	A1
20040049224	Buehlmann et al.	Mar 2004	A1
20040049226	Keegan et al.	Mar 2004	A1
20040049262	Obermiller et al.	Mar 2004	A1
20040049266	Anduiza et al.	Mar 2004	A1
20040059409	Stenzel	Mar 2004	A1
20040073198	Gilson et al.	Apr 2004	A1
20040082904	Houde et al.	Apr 2004	A1
20040082967	Broome et al.	Apr 2004	A1
20040087982	Eskur	May 2004	A1
20040088045	Cox	May 2004	A1
20040093016	Root et al.	May 2004	A1
20040093060	Seguin et al.	May 2004	A1
20040097788	Mourlas et al.	May 2004	A1
20040098022	Barone	May 2004	A1
20040098098	McGuckin, Jr. et al.	May 2004	A1
20040098099	McCullagh et al.	May 2004	A1
20040098112	DiMatteo et al.	May 2004	A1
20040107004	Levine et al.	Jun 2004	A1
20040111096	Tu et al.	Jun 2004	A1
20040116951	Rosengart	Jun 2004	A1
20040117004	Osborne et al.	Jun 2004	A1
20040117009	Cali et al.	Jun 2004	A1
20040122468	Yodfat et al.	Jun 2004	A1
20040122516	Fogarty et al.	Jun 2004	A1
20040127936	Salahieh et al.	Jul 2004	A1
20040127979	Wilson et al.	Jul 2004	A1
20040133274	Webler et al.	Jul 2004	A1
20040138694	Tran et al.	Jul 2004	A1
20040138742	Myers et al.	Jul 2004	A1
20040138743	Myers et al.	Jul 2004	A1
20040148018	Carpentier et al.	Jul 2004	A1
20040148021	Cartledge et al.	Jul 2004	A1
20040153094	Dunfee et al.	Aug 2004	A1
20040158277	Lowe et al.	Aug 2004	A1
20040167565	Beulke et al.	Aug 2004	A1
20040167620	Ortiz et al.	Aug 2004	A1
20040181140	Falwell et al.	Sep 2004	A1
20040186558	Pavcnik et al.	Sep 2004	A1
20040186563	Lobbi	Sep 2004	A1
20040193261	Berreklouw	Sep 2004	A1
20040199245	Lauterjung	Oct 2004	A1
20040204755	Robin	Oct 2004	A1
20040210304	Seguin et al.	Oct 2004	A1
20040210306	Quijano et al.	Oct 2004	A1
20040210307	Khairkhahan	Oct 2004	A1
20040215331	Chew et al.	Oct 2004	A1
20040215333	Duran et al.	Oct 2004	A1
20040215339	Drasler et al.	Oct 2004	A1
20040220655	Swanson et al.	Nov 2004	A1
20040225321	Krolik et al.	Nov 2004	A1
20040225353	McGuckin, Jr. et al.	Nov 2004	A1
20040225354	Allen et al.	Nov 2004	A1
20040225355	Stevens	Nov 2004	A1
20040243221	Fawzi et al.	Dec 2004	A1
20040254636	Flagle et al.	Dec 2004	A1
20040260390	Sarac et al.	Dec 2004	A1
20050010287	Macoviak et al.	Jan 2005	A1
20050021136	Xie et al.	Jan 2005	A1
20050033398	Seguin	Feb 2005	A1
20050033402	Cully et al.	Feb 2005	A1
20050043711	Corcoran et al.	Feb 2005	A1
20050043757	Arad et al.	Feb 2005	A1
20050043790	Seguin	Feb 2005	A1
20050049692	Numamoto et al.	Mar 2005	A1
20050049696	Siess et al.	Mar 2005	A1
20050055088	Liddicoat et al.	Mar 2005	A1
20050060016	Wu et al.	Mar 2005	A1
20050060029	Le et al.	Mar 2005	A1
20050065594	DiMatteo et al.	Mar 2005	A1
20050075584	Cali	Apr 2005	A1
20050075662	Pedersen et al.	Apr 2005	A1
20050075712	Biancucci et al.	Apr 2005	A1
20050075717	Nguyen et al.	Apr 2005	A1
20050075719	Bergheim	Apr 2005	A1
20050075724	Svanidze et al.	Apr 2005	A1
20050075730	Myers et al.	Apr 2005	A1
20050075731	Artof et al.	Apr 2005	A1
20050085841	Eversull et al.	Apr 2005	A1
20050085842	Eversull et al.	Apr 2005	A1
20050085843	Opolski et al.	Apr 2005	A1
20050085890	Rasmussen et al.	Apr 2005	A1
20050090846	Pedersen et al.	Apr 2005	A1
20050090890	Wu et al.	Apr 2005	A1
20050096692	Linder et al.	May 2005	A1
20050096734	Majercak et al.	May 2005	A1
20050096735	Hojeibane et al.	May 2005	A1
20050096736	Osse et al.	May 2005	A1
20050096738	Cali et al.	May 2005	A1
20050100580	Osborne et al.	May 2005	A1
20050107822	Wasdyke	May 2005	A1
20050113910	Paniagua et al.	May 2005	A1
20050131438	Cohn	Jun 2005	A1
20050137683	Hezi-Yamit et al.	Jun 2005	A1
20050137686	Salahieh et al.	Jun 2005	A1
20050137687	Salahieh et al.	Jun 2005	A1
20050137688	Salahieh et al.	Jun 2005	A1
20050137689	Salahieh et al.	Jun 2005	A1
20050137690	Salahieh et al.	Jun 2005	A1
20050137691	Salahieh et al.	Jun 2005	A1
20050137692	Haug et al.	Jun 2005	A1
20050137693	Haug et al.	Jun 2005	A1
20050137694	Haug et al.	Jun 2005	A1
20050137695	Salahieh et al.	Jun 2005	A1
20050137696	Salahieh et al.	Jun 2005	A1
20050137697	Salahieh et al.	Jun 2005	A1
20050137698	Salahieh et al.	Jun 2005	A1
20050137699	Salahieh et al.	Jun 2005	A1
20050137701	Salahieh et al.	Jun 2005	A1
20050137702	Haug et al.	Jun 2005	A1
20050143807	Pavcnik et al.	Jun 2005	A1
20050143809	Salahieh et al.	Jun 2005	A1
20050149159	Andreas et al.	Jul 2005	A1
20050165352	Henry et al.	Jul 2005	A1
20050165477	Anduiza et al.	Jul 2005	A1
20050165479	Drews et al.	Jul 2005	A1
20050182486	Gabbay	Aug 2005	A1
20050197694	Pai et al.	Sep 2005	A1
20050197695	Stacchino et al.	Sep 2005	A1
20050203549	Realyvasquez	Sep 2005	A1
20050203614	Forster et al.	Sep 2005	A1
20050203615	Forster et al.	Sep 2005	A1
20050203616	Cribier	Sep 2005	A1
20050203617	Forster et al.	Sep 2005	A1
20050203618	Sharkawy et al.	Sep 2005	A1
20050209580	Freyman	Sep 2005	A1
20050228472	Case et al.	Oct 2005	A1
20050228495	Macoviak	Oct 2005	A1
20050234546	Nugent et al.	Oct 2005	A1
20050240200	Bergheim	Oct 2005	A1
20050240262	White	Oct 2005	A1
20050251250	Verhoeven et al.	Nov 2005	A1
20050251251	Cribier	Nov 2005	A1
20050261759	Lambrecht et al.	Nov 2005	A1
20050267560	Bates	Dec 2005	A1
20050283231	Haug et al.	Dec 2005	A1
20050283962	Boudjemline	Dec 2005	A1
20060004439	Spenser et al.	Jan 2006	A1
20060004442	Spenser et al.	Jan 2006	A1
20060015168	Gunderson	Jan 2006	A1
20060058872	Salahieh et al.	Mar 2006	A1
20060149360	Schwammenthal et al.	Jul 2006	A1
20060155312	Levine et al.	Jul 2006	A1
20060161249	Realyvasquez et al.	Jul 2006	A1
20060173524	Salahieh et al.	Aug 2006	A1
20060195183	Navia et al.	Aug 2006	A1
20060253191	Salahieh et al.	Nov 2006	A1
20060259134	Schwammenthal et al.	Nov 2006	A1
20060271166	Thill et al.	Nov 2006	A1
20060287668	Fawzi et al.	Dec 2006	A1
20060287717	Rowe et al.	Dec 2006	A1
20070010876	Salahieh et al.	Jan 2007	A1
20070010877	Salahieh et al.	Jan 2007	A1
20070016286	Herrmann et al.	Jan 2007	A1
20070055340	Pryor	Mar 2007	A1
20070061008	Salahieh et al.	Mar 2007	A1
20070112355	Salahieh et al.	May 2007	A1
20070118214	Salahieh et al.	May 2007	A1
20070162107	Haug et al.	Jul 2007	A1
20070173918	Dreher et al.	Jul 2007	A1
20070203503	Salahieh et al.	Aug 2007	A1
20070244552	Salahieh et al.	Oct 2007	A1
20070288089	Gurskis et al.	Dec 2007	A1
20080009940	Cribier	Jan 2008	A1
20080033541	Gelbart et al.	Feb 2008	A1
20080082165	Wilson et al.	Apr 2008	A1
20080125859	Salahieh et al.	May 2008	A1
20080188928	Salahieh et al.	Aug 2008	A1
20080208328	Antocci et al.	Aug 2008	A1
20080208332	Lamphere et al.	Aug 2008	A1
20080221672	Lamphere et al.	Sep 2008	A1
20080234814	Salahieh et al.	Sep 2008	A1
20080255661	Straubinger et al.	Oct 2008	A1
20080269878	Iobbi	Oct 2008	A1
20080288054	Pulnev et al.	Nov 2008	A1
20090005863	Goetz et al.	Jan 2009	A1
20090030512	Thielen et al.	Jan 2009	A1
20090054969	Salahieh et al.	Feb 2009	A1
20090076598	Salahieh et al.	Mar 2009	A1
20090093877	Keidar et al.	Apr 2009	A1
20090171456	Kveen et al.	Jul 2009	A1
20090222076	Figulla et al.	Sep 2009	A1
20090264759	Byrd	Oct 2009	A1
20090264997	Salahieh et al.	Oct 2009	A1
20090299462	Fawzi et al.	Dec 2009	A1
20100049313	Alon et al.	Feb 2010	A1
20100094399	Dorn et al.	Apr 2010	A1
20100121434	Paul et al.	May 2010	A1
20100191326	Alkhatib	Jul 2010	A1
20100219092	Salahieh et al.	Sep 2010	A1
20100280495	Paul et al.	Nov 2010	A1
20110257735	Salahieh et al.	Oct 2011	A1
20110276129	Salahieh et al.	Nov 2011	A1
20120016469	Salahieh et al.	Jan 2012	A1
20120016471	Salahieh et al.	Jan 2012	A1
20120022642	Haug et al.	Jan 2012	A1
20120029627	Salahieh et al.	Feb 2012	A1
20120041549	Salahieh et al.	Feb 2012	A1
20120041550	Salahieh et al.	Feb 2012	A1
20120046740	Paul et al.	Feb 2012	A1
20120053683	Salahieh et al.	Mar 2012	A1
20120089224	Haug et al.	Apr 2012	A1
20120132547	Salahieh et al.	May 2012	A1
20120197379	Laske et al.	Aug 2012	A1
20120330409	Haug et al.	Dec 2012	A1
20130013057	Salahieh et al.	Jan 2013	A1
20130018457	Gregg et al.	Jan 2013	A1
20130030520	Lee et al.	Jan 2013	A1
20130123796	Sutton et al.	May 2013	A1
20130158656	Sutton et al.	Jun 2013	A1
20130190865	Anderson	Jul 2013	A1
20130304199	Sutton et al.	Nov 2013	A1
20140018911	Zhou et al.	Jan 2014	A1
20140094904	Salahieh et al.	Apr 2014	A1
20140114405	Paul et al.	Apr 2014	A1
20140114406	Salahieh et al.	Apr 2014	A1
20140121766	Salahieh et al.	May 2014	A1
20140135912	Salahieh et al.	May 2014	A1
20140243967	Salahieh et al.	Aug 2014	A1

Foreign Referenced Citations (142)

Number	Date	Country
1338951	Mar 2002	CN
19532846	Mar 1997	DE
19546692	Jun 1997	DE
19857887	Jul 2000	DE
19907646	Aug 2000	DE
10049812	Apr 2002	DE
10049813	Apr 2002	DE
10049814	Apr 2002	DE
10049815	Apr 2002	DE
0103546	May 1988	EP
0144167	Nov 1989	EP
0409929	Apr 1997	EP
0850607	Jul 1998	EP
0597967	Dec 1999	EP
1000590	May 2000	EP
1057459	Dec 2000	EP
1057460	Dec 2000	EP
1088529	Apr 2001	EP
0937439	Sep 2003	EP
1340473	Sep 2003	EP
1356793	Oct 2003	EP
1042045	May 2004	EP
0819013	Jun 2004	EP
1430853	Jun 2004	EP
1472996	Nov 2004	EP
1229864	Apr 2005	EP
1059894	Jul 2005	EP
1078610	Aug 2005	EP
1570809	Sep 2005	EP
1576937	Sep 2005	EP
1582178	Oct 2005	EP
1582179	Oct 2005	EP
1469797	Nov 2005	EP
1600121	Nov 2005	EP
1156757	Dec 2005	EP
1616531	Jan 2006	EP
1605871	Jul 2008	EP
2788217	Jul 2000	FR
2826863	Jan 2003	FR
2056023	Mar 1981	GB
2398245	Aug 2004	GB
1271508	Nov 1986	SU
1371700	Feb 1988	SU
9117720	Nov 1991	WO
9217118	Oct 1992	WO
9301768	Feb 1993	WO
9315693	Aug 1993	WO
9504556	Feb 1995	WO
9529640	Nov 1995	WO
9614032	May 1996	WO
9624306	Aug 1996	WO
9640012	Dec 1996	WO
9829057	Jul 1998	WO
9836790	Aug 1998	WO
9850103	Nov 1998	WO
9857599	Dec 1998	WO
9933414	Jul 1999	WO
9940964	Aug 1999	WO
9944542	Sep 1999	WO
9947075	Sep 1999	WO
0009059	Feb 2000	WO
0041652	Jul 2000	WO
0044308	Aug 2000	WO
0044311	Aug 2000	WO
0044313	Aug 2000	WO
0045874	Aug 2000	WO
0047139	Aug 2000	WO
0049970	Aug 2000	WO
0067661	Nov 2000	WO
0105331	Jan 2001	WO
0108596	Feb 2001	WO
0110320	Feb 2001	WO
0110343	Feb 2001	WO
0135870	May 2001	WO
0149213	Jul 2001	WO
0154625	Aug 2001	WO
0162189	Aug 2001	WO
0164137	Sep 2001	WO
0176510	Oct 2001	WO
0197715	Dec 2001	WO
0236048	May 2002	WO
0241789	May 2002	WO
0243620	Jun 2002	WO
0247575	Jun 2002	WO
02056955	Jul 2002	WO
02100297	Dec 2002	WO
03003943	Jan 2003	WO
03003949	Jan 2003	WO
03011195	Feb 2003	WO
03028592	Apr 2003	WO
03030776	Apr 2003	WO
03037227	May 2003	WO
03047648	Jun 2003	WO
03015851	Nov 2003	WO
03094793	Nov 2003	WO
03094797	Nov 2003	WO
2004006803	Jan 2004	WO
2004006804	Jan 2004	WO
2004014256	Feb 2004	WO
2004019811	Mar 2004	WO
2004019817	Mar 2004	WO
2004021922	Mar 2004	WO
2004023980	Mar 2004	WO
2004026117	Apr 2004	WO
2004041126	May 2004	WO
2004043293	May 2004	WO
2004047681	Jun 2004	WO
2004058106	Jul 2004	WO
2004066876	Aug 2004	WO
2004082536	Sep 2004	WO
2004089250	Oct 2004	WO
2004089253	Oct 2004	WO
2004093728	Nov 2004	WO
2004105651	Dec 2004	WO
2005002466	Jan 2005	WO
2005004753	Jan 2005	WO
2005009285	Feb 2005	WO
2005011534	Feb 2005	WO
2005011535	Feb 2005	WO
2005023155	Mar 2005	WO
2005027790	Mar 2005	WO
2005046528	May 2005	WO
2005046529	May 2005	WO
2005048883	Jun 2005	WO
2005062980	Jul 2005	WO
2005065585	Jul 2005	WO
2005084595	Sep 2005	WO
2005087140	Sep 2005	WO
2005096993	Oct 2005	WO
2006005015	Jan 2006	WO
2006009690	Jan 2006	WO
2006027499	Mar 2006	WO
2006138391	Dec 2006	WO
2007033093	Mar 2007	WO
2007035471	Mar 2007	WO
2007044285	Apr 2007	WO
2007053243	May 2007	WO
2007058847	May 2007	WO
2007092354	Aug 2007	WO
2007097983	Aug 2007	WO
2010042950	Apr 2010	WO
2012116368	Aug 2012	WO

Non-Patent Literature Citations (45)

Entry
Andersen et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J., 13:704-708, May 1992.
Atwood et al., “Insertion of Heart Valves by Catheterization.” Project Supervised by Prof. S. Muftu of Northeastern University 2001-2002: 36-40, May 30, 2002.
Bodnar et al., “Replacement Cardiac Valves R Chapter 13: Extinct Cardiac Valve Prostheses.” Pergamon Publishing Corporation. New York, 307-322, 1991.
Boudjemline et al., “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study.” Med Sci. Monit., vol. 8, No. 4: BR113-116, Apr. 12, 2002.
Boudjemline et al., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs ” Euro. Heart J., 23: 1045-1049, Jul. 2002.
Boudjemline et al., “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study.” Journal of the American College of Cardiology, vol. 43(6): 1082-1087, Mar. 17, 2004.
Boudjemline et al., “Percutaneous Valve Insertion: A New Approach?” J. of Thoracic and Cardio. Surg, 125(3): 741-743, Mar. 2003.
Boudjemline et al., “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation, 105: 775-778, Feb. 12, 2002.
Cribier et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coll. of Cardio, 43(4): 698-703, Feb. 18, 2004.
Cribier et al., “Percutaneous Transcatheter Implementation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description.” Circulation, 106: 3006-3008, Dec. 10, 2002.
Cribier et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” Percutaneous Valve Technologies, Inc., 16 pages, Apr. 16, 2002.
Ferrari et al., “Percutaneous Transvascular Aortic Valve Replacement with Self-Expanding Stent-Valve Device.” Poster from the presentation given at SMIT 2000, 12th International Conference. Sep. 5, 2000.
Hijazi, “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardio., 43(6): 1088-1089, Mar. 17, 2004.
Huber et al., “Do Valved Stents Compromise Coronary Flow?” European Journal of Cardio-thoracic Surgery, vol. 25: 754-759, Jan. 23, 2004.
Knudsen et al., “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs, 16(5): 253-262, May 1993.
Kort et al., “Minimally Invasive Aortic Valve Replacement: Echocardiographic and Clinical Results.” Am. Heart J., 142(3): 476-481, Sep. 2001.
Love et al., The Autogenous Tissue Heart Valve: Current Status. Journal of Cardiac Surgery, 6(4): 499-507, Mar. 1991.
Lutter et al., “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation.” J. of Thoracic and Cardio. Surg., 123(4): 768-776, Apr. 2002.
Moulopoulos et al., “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg., 11(5): 423-430, May 1971.
Paniagua et al., “Percutaneous Heart Valve in the Chronic in Vitro Testing Model.” Circulation, 106: e51-e52, Sep. 17, 2002.
Paniagua et al., “Heart Watch.” Texas Heart Institute. Edition: 8 pages, Spring, 2004.
Pavcnik et al., “Percutaneous Bioprosthetic Venous Valve: A Long-term Study in Sheep.” J. of Vascular Surg., 35(3): 598-603, Mar. 2002.
Phillips et al., “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency.” Annals of Thoracic Surg., 21(2): 134-136, Feb. 1976.
Sochman et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Intervent. Radiol., 23: 384-388, Sep. 2000.
Stuart, “In Heart Valves, A Brave, New Non-Surgical World.” Start-Up. Feb. 9-17, 2004.
Vahanian et al., “Percutaneous Approaches to Valvular Disease.” Circulation, 109: 1572-1579, Apr. 6, 2004.
Van Herwerden et al., “Percutaneous Valve Implantation: Back to the Future?” Euro. Heart J., 23(18): 1415-1416, Sep. 2002.
Zhou et al, “Self-expandable Valved Stent of Large Size: Off-Bypass Implantation in Pulmonary Position.” Eur. J. Cardiothorac, 24: 212-216, Aug. 2003.
“A Matter of Size.” Triennial Review of the National Nanotechnology Initiative, The National Academies Press, Washington DC, v-13, http://www.nap.edu/catalog/11752/a-matter-of-size-triennial-review-of-the-national-nanotechnology, 2006.
Atwood et al., “Insertion of Heart Valves by Catheterization.” The Capstone Design Course Report. MIME 1501-1502. Technical Design Report. Northeastern University, pp. 1-93, Nov. 5, 2007.
Supplemental Search Report from EP Patent Office, EP Application No. 04813777.2, dated Aug. 19, 2011.
Supplemental Search Report from EP Patent Office, EP Application No. 04815634.3, dated Aug. 19, 2011.
Cunanan et al., “Tissue Characterization and Calcification Potential of Commercial Bioprosthetic Heart Valves.” Ann. Thorac. Surg., S417-421, May 15, 2001.
Cunliffe et al., “Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Heart Tissue.” Applied and Environmental Microbiology, Greenport, New York, 37(5): 1044 1046, May 1979.
EP Search Report for EP Application No. 06824992.9, dated Aug. 10, 2011.
“Heart Valve Materials—Bovine (cow).” Equine & Porcine Pericardium, Maverick Biosciences Pty. Lt, http://maverickbio.com/biological-medical-device-materials.php?htm. 2009.
Helmus, “Mechanical and Bioprosthetic Heart Valves in Biomaterials for Artificial Organs.” Woodhead Publishing Limited: 114-162, 2011.
Hourihan et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks.” JACC, Boston, Massachusetts, 20(6): 1371-1377, Nov. 15, 1992.
Laborde et al., “Percutaneous Implantation of the Corevalve Aortic Valve Prosthesis for Patients Presenting High Risk for Surgical Valve Replacement.” EuroIntervention: 472-474, Feb. 2006.
Levy, “Mycobacterium Chelonei Infection of Porcine Heart Valves.” The New England Journal of Medicine, Washington DC, 297(12), Sep. 22, 1977.
Supplemental Search Report from EP Patent Office, EP Application No. 05758878.2, dated Oct. 24, 2011.
“Pericardial Heart Valves.” Edwards Lifesciences, Cardiovascular Surgery FAQ, http://www.edwards.com/products/cardiovascularsurgeryfaq.htm, Nov. 14, 2010.
Southern Lights Biomaterials Homepage, http://www.slv.co.nz/, Jan. 7, 2011.
Stassano. “Mid-term Results of the Valve-on-Valve Technique for Bioprosthetic Failure.” European Journal of Cardiothoracic Surgery: vol. 18, 453-457, Oct. 2000.
Topol. “Percutaneous Expandable Prosthetic Valves.” Textbook of Interventional Cardiology, W.B. Saunders Company, 2: 1268-1276, 1994.

Related Publications (1)

	Number	Date	Country
	20180104055 A1	Apr 2018	US

Divisions (1)

	Number	Date	Country
Parent	12269213	Nov 2008	US
Child	12492512		US

Continuations (5)

	Number	Date	Country
Parent	15658255	Jul 2017	US
Child	15842215		US
Parent	14873462	Oct 2015	US
Child	15658255		US
Parent	14669738	Mar 2015	US
Child	14873462		US
Parent	12492512	Jun 2009	US
Child	14669738		US
Parent	10870340	Jun 2004	US
Child	12269213		US

Everting heart valve

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract